Attached files
| file | filename |
|---|---|
| EX-32.2 - CERTIFICATION - Xenacare Holdings, Inc. | xena_ex32z2.htm |
| EX-32.1 - CERTIFICATION - Xenacare Holdings, Inc. | xena_ex32z1.htm |
| EX-10.4 - AGREEMENT - Xenacare Holdings, Inc. | xena_ex10z4.htm |
| EX-31.1 - CERTIFICATION - Xenacare Holdings, Inc. | xena_ex31z1.htm |
| EX-31.2 - CERTIFICATION - Xenacare Holdings, Inc. | xena_ex31z2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
———————
FORM 10-K
———————
þ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE |
| ACT OF 1934 |
For the fiscal year ended: December 31, 2010 | |
or | |
|
|
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE |
| ACT OF 1934 |
For the transition period from: _____________ to _____________ | |
XenaCare Holdings, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Florida | 000-53916 | 20-3075747 |
(State or Other Jurisdiction | (Commission | (I.R.S. Employer |
6001 Broken Sound Parkway, Suite 630
Boca Raton, Florida 33487
(Address of Principal Executive Office) (Zip Code)
(561) 496-6676
(Registrant’s telephone number, including area code)
———————
Securities registered pursuant to Section 12(b) of the Act: | ||
| None |
|
Securities registered pursuant to Section 12(g) of the Act: | ||
| (Title of Class) |
|
Common Stock, $0.001 par value per share
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes ¨ No þ
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ¨ No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T(S.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K. Yes ¨ No þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ |
| Accelerated filer ¨ |
Non-accelerated filer ¨ | (Do not check if a smaller reporting company) | Smaller reporting company þ |
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ¨ No þ
The aggregate market value of the Company's voting stock held by non-affiliates as of June 30, 2010 was approximately $9,810,111 based on the average closing bid and asked prices of such stock on that date as quoted on the Over the-Counter Bulletin Board.
There were 77,012,772 shares of common stock outstanding as of March 31, 2011.
XENACARE HOLDINGS, INC.
INDEX
ii
This annual report on Form 10-K (“Report”) contains forward-looking statements. For this purpose, any statements contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements, including any statements relating to future actions and outcomes including but not limited to prospective products, future performance or results of current or anticipated products, sales and marketing efforts, costs and expense trends, future interest rates, outcome of contingencies and their future impact on financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management, and other matters. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "expects," “anticipates," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," “may,” “will,” “should,” “contemplates,” “predicts,” “potential,” or “continue” or variations and/or the negative of these similar terms. Forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company, us, our future performance, our beliefs and our Management's assumptions. All forward-looking statements made in this Report, including any future written or oral statements made by us or on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that we cannot predict. Any assumptions, upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this Report. Therefore, actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In evaluating these forward-looking statements, you should consider various factors, including the following: (a) those risks and uncertainties related to general economic conditions, (b) whether we are able to manage our planned growth efficiently and operate profitable operations, (c) whether we are able to generate sufficient revenues or obtain financing to sustain and grow our operations, (d) whether we are able to successfully fulfill our primary requirements for cash, which are explained below under “Liquidity and Capital Resources”. We assume no obligation to update forward-looking statements, except as otherwise required under the applicable federal securities laws.
iii
ITEM 1
BUSINESS
Organization and Overview
XenaCare Holdings, Inc. (the “Company”, “XenaCare”, “XC Holdings”, “we”, “us” or “our”) was organized under the laws of Florida in June 2005 to formulate, market and distribute a line of clinical and protective nutrition supplement products (“NSPs”) as well as homeopathic medication, detoxification and pet care products.
Our Clinical NSP products group includes our proprietary formulations - XenaCor, XenaTri and XenaZyme Plus, which will be sold through mass media buys (radio and television advertising), web sales and other channels of distribution.
On September 29, 2010, XenaCare Holdings entered into a Private Labeling Agreement with Renaissance Health Publishing, LLC of Boca Raton, Florida to market our clinical products. These products address major issues concerning prevention of heart disease. XenaCare will provide the finished products to Renaissance Health who is currently developing the labels, the marketing materials and strategies for these retail products. Because the Renaissance model is to educate the consumer through direct response sales, these unique supplements will necessarily receive greater personal attention by the consumer.
Our Protective NSP product group is directed to the energy/lifestyle performance market. Our initial product, SunPill™, is formulated to protect the skin when exposed to damaging ultraviolet rays. However, during the third quarter of 2010, we had the product reevaluated and as a result were able to extend the shelf life for an additional two years. We are currently in negotiations with a distributor in Cypress to assume the entire line for distribution in the European market. We believe that we will able to recover our product costs however because of certain delays in consummating the Cypress sale we have fully impaired the inventory in fourth quarter of 2010.
Our Homeopathic Medication product line is led by Cobroxin. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Available in a topical gel that relieves pain associated with joints, repetitive stress and arthritis, and in an oral spray that is formulated to relieve lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, Cobroxin™ is derived from cobra venom.
Our Detoxification product line is led by Zeolite. We exclusively market and distribute Zeolite from Mineral Sciences, LLC within the United States. Zeolite is a cellular cleanse and detoxification product designed as an effective solution for removing heavy metals and toxins from the body. Research has also shown that the product’s ingredients may help reduce viral replication and support healthy blood sugar levels. Additionally, this product improves nutrient absorption, supports immune system function and reduces symptoms of allergies.
Our new Pet Care product line is led by EstraPet™. On September 8, 2010, XenaCare Holdings entered into an exclusive agreement with Dr. Phillip Schoenwetter whereby XenaCare gained all rights to the trademark EstraPet™; to the domain www.estrapet.com and to the United States Patent Pending under the caption "Treatment for Domestic Animals Having Sex Hormone Deficiencies using Soy Germ Isoflavones". EstraPet™ answers the need for treating the unintended consequences caused by spaying and neutering and is the only known natural hormone modulator available on the market today.
We have existing agreements for manufacturing, packaging and distribution and fulfillment of our products. We have also engaged 205 broker/consultants and Song Partners, a New York advertising firm, to assist us in marketing, web hosting and the development and production of infomercials.
Most of our revenues to date have been generated in 2010, from the sales of Cobroxin starting in mid-October 2009. We have distribution channels, direct response, catalogs, mass food and drug retailers, online and through infomercials, established in the fourth quarter of 2009, and expanded in 2010.
References throughout this document to “XenaCare Holdings,” “XenaCare,” “the Company,” “we,” “us” and “our” refer to XenaCare Holdings, Inc., a Florida corporation and our subsidiaries.
1
History
While the Company was organized in 2005, its predecessor, XenaCare LLC was organized in 2001. Thereafter, the Company entered into an exchange agreement with certain members of XenaCare LLC and such members exchanged their interest in XenaCare LLC for an aggregate of 800,000 shares of XenaCare Holdings, Inc. common stock, which represented a value of $1,600,000.
In August 2008, XenaCare entered into a Share Exchange Agreement and Plan of Reorganization with Sun Packing, Inc. (“Sun”) Wallisville Partners, Ltd and Jon Grossman and Peter Elston, shareholders of Sun, in which XenaCare would have received 100% of the outstanding shares of Sun in exchange for 33.8% of XenaCare’s outstanding common shares on a fully diluted basis. XenaCare borrowed approximately $977,000 from Sun Packing, Inc. On December 22, 2008, XenaCare received notice from Jon Grossman, Chairman of Sun, to terminate the Share Exchange Agreement and Plan of Reorganization. Sun claimed a right to terminate due to Sun’s inability to receive consent from its lender, Frost Bank of Houston, Texas, to complete the business combination. XenaCare, after careful consideration of its options, has elected to accept the termination from Sun.
On January 5, 2009, XenaCare amended its Articles of Incorporation to increase the number of authorized shares of common stock from 45 million to 200 million.
In May 2009, NutraPharma, Inc. awarded to XenaCare the US marketing rights to Cobroxin. NutraPharma is a biotechnology company that is developing treatments for adrenomyeloneuropathy, HIV and multiple sclerosis. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. The Company has sales agreements with many major retailers.
In September 2010, XenaCare Holdings entered into an exclusive agreement with Dr. Phillip Schoenwetter whereby XenaCare gained all rights to the trademark EstraPet™; to the domain www.estrapet.com and to the United States Patent Pending under the caption "Treatment for Domestic Animals Having Sex Hormone Deficiencies using Soy Germ Isoflavones". EstraPet answers the need for treating the unintended consequences caused by spaying and neutering and is the only known natural hormone modulator available on the market today.
During the third quarter of 2010, the Company entered into a new image marketing and branding agreement with Creative Management, Inc. and a companion spokesperson agreement with Dr. Bob Arnot, a nationally known medical and news correspondent. The terms of the agreements provide for image marketing and branding services for 36 months. The contract was prepaid through the issuance of 500,000 common shares valued at $.12 each, the fair value of the shares at the execution of the agreement.
Operations
Homeopathic Medication
The present focus of the Company is the sale of Cobroxin. On May 26, 2009 XenaCare was awarded the US marketing rights from Nutra Pharma, Inc. Cobroxin is the first over-the-counter pain reliever clinically proven to treat chronic pain. Cobroxin is available as an oral spray for lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, and as a topical gel for repetitive stress, arthritis and joint pain. Cobroxin is a derivative of cobra venom is all-natural, non-addictive, non-narcotic, non-opiate, long lasting and in some clinical tests proven to be more effective than morphine.
XenaCare is supporting its fast-growing network of retailers carrying Cobroxin with a comprehensive multi-million dollar national advertising campaign that includes direct response, print media, television commercials and national sponsorship programs. We market and distribute our products through a variety of retail outlets, including chain drug stores, independent pharmacies, grocery chains, mass marketers, catalog companies and e-commerce sites. Cobroxin was marketed through Internet sales during the last quarter of 2009, and in 2010 the product has been accepted by 40% of the 105,000 retail stores (as reported in the trade publication, Chain Drug Review) selling healthcare products across the country. Analgesic products average 21 inventory turnovers per year and are among the fastest sellers in drug stores. In 2010, two customers represented 39.5% and 31.5% of sales.
XenaCare has purchased advertising in a comprehensive array of men’s, women’s and specialty magazines. The ads made their debut in November 2009 and in the first quarter of 2010 generated about 108 million reader impressions. Cobroxin will also be featured through the distribution of 18 million retail catalogs throughout the US.
2
Additionally, the Company is authorized to use the American Arthritis Foundation’s logo on packaging, Websites, Customer websites and to send out direct mailings to 100,000 Arthritis foundation members. XenaCare Holdings advertised in the 2010 Super Bowl XLIV Game Program, the NFL Alumni Guide program and Yearbook, and in the 2010 NBA All-star as well as in the official annual publication of NASCAR that was seen by 8,000,000 attendees. XenaCare is also advertising in Prevention, Arthritis Today, Shape, Allure, Woman’s Day, Men’s Journal, Martha Stewart Living and Redbook. Television commercials were also successfully market-tested in the third quarter of 2010. XenaCare has also contracted to publish Cobroxin advertisements in 2010 Major League Baseball (MLB) yearbooks. The advertisements are scheduled to run in the yearbooks of 6 major league cities, including the New York Mets, the Los Angeles Dodgers and the Chicago Cubs, and represents approximately seven times the viewership of that of the NCAA advertising campaign. In addition to its marketing campaigns, XenaCare is participating in an athletic sponsorship with Megan Wallin, a professional beach volleyball player on the AVP Tour. Megan, a Florida native, has proven to be a strong force on the sand and in the world of business and has had six professional wins and 10 finals appearances in 2009; she also competed against the two-time gold medalists from the 2004 Athens Olympics and 2008 Beijing Olympics. Her goal 2010 is to make the U.S. Olympic, Megan is rated #1 in Florida and in the top 30 in the world.
Cobroxin is available to independent pharmacy owners through membership in the Chain Drug Marketing Association (CDMA), one of the largest pharmacy organizations representing more than 6,000 outlets in 32 states. Additionally, Cobroxin is sold through most major drugstore chains, mass marketers, Cardinal Wholesale, a $100/B health care distributor, and food giants, as well as online at: Cobroxin.com, Amazon.com, Overstock.com and Drugstore.com. More than 200 brokers also Market Cobroxin through retail outlets.
During the first quarter of 2010, the Company entered into agreements for the sale of Cobroxin through major retail outlets. Although some of the retailers listed have not yet ordered product at the filing of this report, agreements are in place for all of them. These agreements do not require the customers to purchase any particular amounts of the product.
AMAZON.COM
AMERIMARK
BENCHMARK
CARDINAL WHOLESALE
CDMA
CVS
DERMADOCTOR
DR. LEONARD’S\
DRUG EMPORIUM
DRUGSTORE.COM
DUANE READE
EVITAMINS
HARDTOFIND BRANDS
HD SMITH
HEALTHY PETS
IMPERIAL DISTRIBUTORS
JOHNSON SMITH
KERR DRUG
KINNEY DRUG
MAX-WELNESS
MEIJER
NATURAL HEALTH CENTER
MUTUAL DRUG CO.
OVERSTOCK.COM
UNIVERSAL DIRECT (SUPPORT PLUS)
QUICK2YOU
VALUE DRUG
VITAMIN/PURITAN PRIDE
WALGREENS
WINN DIXIE
Pet Care
EstraPet™ is a treatment for domestic animals having sex hormone deficiencies utilizing patent pending process of Soy Germ Isoflavones. EstraPet™ answers the need for treating the unintended consequences caused by spaying and neutering and is the only known natural hormone modulator available on the market today.
Protective NSP
During 2010 the Company has been attempting the liquidation of this merchandize along with any bulk product, however as a result of delays in consummating a final sale, the Company has fully impaired the SunPill® inventory, even though the SunPill® inventory has been retested and the shelf life has been extended for two years.
Clinical NSP
XenaCare’s Clinical products seek to shift a portion of current consumer “out-of-pocket” spending on non-effective and/or incomplete self-care performance and healing products obtained through myriad retail and Internet
3
distribution systems. Our Clinical NSPs provide consumers with access to proprietary nutritional supplements that supplement nutrient depletion resulting from the use of certain prescription pharmaceuticals. We plan to also sell and distribute these products through pharmacies and other distribution outlets as well as through infomercials.
XenaCor, XenaTri and XenaZymePlus are specifically formulated to support and help maintain the doctor directed patient healthcare for many risk factors, including those related to homocysteine levels, lipid control, blood flow and blood pressure. These NSPs are formulated under the guidelines of the Food and Drug Administration (“FDA”) and its regulation of the Dietary Supplement and Health Education Act. However, while the FDA regulates the dietary supplement industry, no approvals by the FDA are required for our products. As discussed below under “Government Regulation”, the FDA oversees product safety, manufacturing, and product information, such as claims on the product’s label, package inserts, and accompanying literature.
We believe our XenaCare Clinical NSPs below support and maintain the following:
·
XenaCor: the lowering of serum cholesterol, C-reactive protein and homocysteine levels. This product was designed to support cardiovascular health.
·
XenaTri: the lowering of triglycerides and raising of HDL. This product was designed to support cardiovascular health.
·
XenaZyme Plus: increases the body’s oxygen carrying capacities. This product was designed to support digestion.
We believe these NSPs significantly differentiate themselves from our competition including self-help vitamin, herbal and purported performance enhancing product manufacturers and distributors. These NSPs are formulated to support the delivery of measurable subjective (improved medical history) and/or objective (laboratory results) effects regardless of what other medications or supplements the patient is taking. We believe that these NSPs support significant positive health actions and outcomes without deleterious adverse side effects. The Company does not diagnose nor treat diseases. Our products are only formulated to support and maintain an individual’s health and well being.
Manufacturing and Supplies
The Company uses contracted third parties to manufacture its products and to provide raw materials. The third party manufacturers are responsible for receipt and storage of raw material, production and packaging, and labeling of finished goods. At present, the Company is dependent upon manufacturers for the production of all of its products. Our primary product Cobroxin is supplied to us under an exclusive distribution agreement from its manufacturer, who owns the formulation. Among other arrangements, the distribution agreement grants the company exclusive distribution rights in the US market provides in exchange for the commitment to purchase $180,000 of product per quarter. To the extent the manufacturers should discontinue their relationship with the Company, sales could be adversely impacted. The Company believes at the present time it will be able to obtain the quantity of products and supplies it will need to meet orders.
We purchase all of our products from third-party suppliers and manufacturers pursuant to purchase orders without any long-term agreements. In the event that a current manufacturer is unable to meet our manufacturing and delivery requirements at some time in the future, we may suffer short-term interruptions of delivery of certain products while we establish an alternative source. While we believe alternative sources are in most cases readily available and we have also established working relationships with several third-party suppliers and manufacturers, none of these agreements are long term. We also rely on third-party carriers for product shipments, including shipments to and from our distribution facilities. We are therefore subject to the risks, including employee strikes and inclement weather, associated with our carrier’s ability to provide delivery services to meet our fulfillment and shipping needs. Failure to deliver products to our customers in a timely and accurate manner would harm our reputation, our business and results of operations.
Competition
The nutritional supplement and personal intimacy industries are highly competitive. Many of the Company’s competitors are large, well-known companies that have considerably greater financial, sales, marketing and technical resources than the Company. Additionally, these competitors have formulary capabilities that may allow them to formulate new or improved products that may compete with product lines the Company markets and distributes. In addition, competitors may elect to devote substantial resources to marketing their products to similar
4
outlets and may choose to develop educational and information programs like those formulated by the Company to support their marketing efforts. The Company’s business, financial condition and results of operations could be materially and adversely affected by any one or more of such developments.
Our nutritional products, in general, compete against similar products distributed by national chain stores, such as GNC and Vitamin Shoppe. Our personal performance products compete against a number of well-known brands. We are unaware of any competitors for our replenishment products, as these products are in their infancy. As the Company’s sales grow, competitors may attempt to introduce products that compete directly against our products. Our failure to adequately respond to the competitive challenges faced by the products it offers could have a material adverse effect on its business, financial condition and results of operations.
Proprietary Rights
The Company regards the protection of copyrights, trademarks and other proprietary rights that it may own or license as material to its future success and competitive position. The Company intends to rely on a combination of laws and contractual restrictions such as confidentiality agreements to establish and protect its proprietary rights. Laws and contractual restrictions, however, may not be sufficient to prevent misappropriation of proprietary rights or deter others from independently formulating products that are substantially equivalent or superior. The Company has no patent protection.
Trademarks Owned by XenaCare
| 1. |
| B-ALERT |
| Registered with USPTO, Registration # 3,251,557 |
| 2. |
| SUN PILL |
| Registered with USPTO on 10/31/2006, Registration # 3,166,408 |
| 3. |
| SUN PILL |
| Registered under Madrid Protocol on 3/2/2006, Registration # 888,076 |
| 4. |
| UV DEFENSE |
| Pending with USPTO, Serial Number 78/564,974 |
| 5. |
| SUN DEFENSE |
| Pending with USPTO, Serial Number 78/564,985 |
| 6. |
| UV ORGANICS |
| Pending with USPTO, Serial Number 78/865,855 |
Governmental Regulation
The FDA regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution and sale of foods, dietary supplements, over-the-counter drugs, and pharmaceuticals. In January 2000, the FDA issued a final rule called “Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body”; in the regulation and its preamble, the FDA distinguished between permitted claims under the Federal Food, Drug and Cosmetic Act relating to the effect of dietary supplements on the structure or functions of the body, and impermissible direct or implied claims of the effect of dietary supplements on any disease.
The Dietary Supplement Health and Education Act of 1994, referred to as DSHEA, revised the provisions of the Federal Food, Drug and Cosmetic Act concerning the composition and labeling of dietary supplements, and statutorily created a new class entitled “dietary supplements.” Dietary supplements include vitamins, minerals, herbs, amino acids, and other dietary substances used to supplement diets. A majority of our products are considered dietary supplements as outlined in the Federal Food, Drug and Cosmetic Act. This act requires us to maintain evidence that a dietary supplement is reasonably safe.
A manufacturer of dietary supplements may make statements concerning the effect of a supplement or a dietary ingredient on the structure or any function of the body, in accordance with the regulations described above. As a result, we make such statements with respect to our products. In some cases, such statements must be accompanied by a statutory statement that the claim has not been evaluated by FDA, and the product is not intended to treat, cure, mitigate or prevent any disease, and FDA must be notified of the claim within 30 days of first use.
The FDA oversees product safety, manufacturing, and product information, such as claims on the product’s label, package inserts, and accompanying literature. The FDA has promulgated regulations governing the labeling and marketing of dietary and nutritional supplement products. The regulations include:
·
The identification of dietary or nutritional supplements and their nutrition and ingredient labeling;
·
requirements related to the wording used for claims about nutrients, health claims, and statements of nutritional support;
5
·
labeling requirements for dietary or nutritional supplements for which “high potency,” “antioxidant,” and “trans-fatty acids” claims are made;
·
notification procedures for statements on dietary and nutritional supplements; and
·
pre-market notification procedures for new dietary ingredients in nutritional supplements.
We utilize a substantiation program that involves the compilation and review of scientific literature pertinent to the ingredients contained in each of our products. We continuously update our substantiation program to expand evidence for each of our product claims and notify the FDA of certain types of performance claims made in connection with our products.
In certain markets, including the United States, specific claims made by us with respect to our products may change the regulatory status of a product. For example, a product sold as a dietary supplement but marketed as a treatment, prevention, or cure for a specific disease or condition would likely be considered by the FDA or other regulatory bodies as unapproved and thus an illegal drug. To maintain the product’s status as a dietary supplement, the labeling and marketing must comply with the provisions in DSHEA and the FDA’s extensive regulations. As a result, we have procedures in place to promote and enforce compliance by our employees related to the requirements of DSHEA, the Food, Drug and Cosmetic Act, and various other regulations. Because of the diverse scope of regulations applicable to our products, and the varied regulators enforcing these regulatory requirements, determining how to conform to all requirements is often open to interpretation and debate. As a result, we can make no assurances that regulators will not question any of our actions in the future, even though we have put continuing effort into complying with all applicable regulations.
Dietary supplements are also subject to the Nutrition, Labeling and Education Act and various other acts that regulate health claims, ingredient labeling, and nutrient content claims that characterize the level of nutrients in a product. These acts prohibit the use of any specific health claim for dietary supplements unless the health claim is supported by significant scientific research and is pre-approved by the FDA.
Regulators such as the FTC regulate marketing practices and advertising of a company and its products. In the past several years, regulators have instituted various enforcement actions against numerous dietary supplement companies for false and/or misleading marketing practices, as well as misleading advertising of certain products. These enforcement actions have resulted in consent decrees and significant monetary judgments against the companies and/or individuals involved. Regulators require a company to convey product claims clearly and accurately, and further require marketers to maintain adequate substantiation for their claims. The FTC requires such substantiation to be competent and reliable scientific evidence.
Specifically, the FTC requires a company to have a reasonable basis for the expressed and implied product claim before it disseminates an advertisement. A reasonable basis is determined based on the claims made, how the claims are presented in the context of the entire advertisement, and how the claims are qualified. The FTC’s standard for evaluating substantiation is designed to ensure that consumers are protected from false and/or misleading claims by requiring scientific substantiation of product claims at the time such claims are first made. The failure to have this substantiation violates the Federal Trade Commission Act.
We do not believe that Stark laws are applicable to our business because all of our products are sold for cash and there are no third party payor Medicare/Medicaid reimbursements.
Labor Force
XenaCare employs six people. In addition, the Company utilizes the services of several consultants on a regular basis. We have 205 brokers who are commissioned salespeople in the field, under a three-year contract. We have a distribution center on a contractual basis, with 180 employees. XenaCare projects that during the next 12 months, its work force is likely to increase.
6
ITEM 1A
RISK FACTORS
Risks Relating to Our Business Generally
We have a history of losses.
We have a history of operating losses in our business and have incurred significant net losses since our inception. Our net losses for the years ended December 31, 2010 and 2009 were $3,388,189 and $2,292,444, respectively. Accumulated deficit at December 31, 2010 totals $12,758,413. There can be no assurance that we will be able to generate revenues in sufficient amounts to generate profits.
If our cash position continues to deteriorate, we will not have sufficient cash to fund our working capital.
Our continued operating losses have contributed to the deterioration of our cash position. Further, we have used a significant amount of our cash for consulting services, web hosting, infomercials, new product inventory and marketing materials including the publication of a book about our products. If we are unable to generate revenues or secure financing on a timely basis, we will not have sufficient cash to fund our working capital and capital expenditure requirements and we may be forced to cease operations. In such event, the shares of our common stock may cease to have any value.
We depend on the services of Frank Rizzo, and a loss of this individual may harm our business.
Our performance is substantially dependent upon the performance of Frank Rizzo and to a less extent, certain other employees. The familiarity of this key employee to his respective industry makes this employee especially critical to our success. We currently have an employment agreement with Mr. Rizzo. The loss of the services of any of our executive officers or key employees may harm our business and the cost to replace such individuals may put a strain on our limited resources.
The nutrition supplement industry is intensely competitive and the strengthening of any of our competitors could harm our business.
The nutrition supplement industry is intensely competitive. Many competitors have greater name recognition and financial resources, which may give them a competitive advantage. Our competitors may also be able to devote greater resources to marketing, promotional, and pricing campaigns that may influence our continuing and potential independent associates and members to buy products from competitors rather than from us. Such competition could adversely affect our business and current market share.
XenaCare may be subject to additional laws or regulations by the Food and Drug Administration or other federal, state or foreign regulatory authorities, subject to the repeal of laws or regulations which we consider favorable, such as the Dietary Supplement Health and Education Act of 1994 (“DSHEA”), or subject to more stringent interpretations of current laws or regulations, from time to time in the future which may adversely impact our business and operations.
We are unable to predict the nature of such future laws, regulations, interpretations or applications, nor can we predict what effect additional governmental regulations or administrative orders, when and if promulgated, would have on our business in the future. We also cannot predict what effect these regulations, and the related publicity from promulgation of such regulations, could have on consumer perceptions related to the nutrition supplement market in which we will operate. The Company depends on positive publicity as it relates to the efficacy and overall health benefits derived from such products. This could have a materially adverse affect on our business, financial condition, results of operations and cash flows. The Food and Drug Administration has also announced that it is considering promulgating new Good Manufacturing Practices regulations, specific to nutrition supplements. Such regulations, if promulgated, may be significantly more rigorous than currently applicable regulations and contain quality assurance requirements similar to Good Manufacturing Practices regulations for drug products. Therefore, we may be required to expend additional capital resources on upgrading manufacturing processes and/or equipment in the future in order to comply with the law. The Food and Drug Administration or other governmental regulatory bodies could require the reformulation of certain products to meet new standards, the recall or discontinuance of certain products not able to be reformulated, imposition of additional record keeping requirements, and expanded documentation of the properties of certain products and expanded or different labeling and scientific substantiation. Any or all of such requirements could have a materially adverse affect on our business, financial condition, results of operations and cash flows. The Company’s failure to comply with applicable Food and
7
Drug Administration regulatory requirements could result in, among other things, injunctions, product withdrawals, recalls, product seizures, fines, and possible criminal prosecutions. Because of the broad language of certain sections of DSHEA and the regulations that implement it, it is difficult for any company manufacturing or making nutrition supplements to remain in strict compliance. If we do not comply we may be subject to penalties.
If our insurance coverage is not sufficient to cover all risk exposure, we may be subject to losses.
XenaCare continues its efforts to maintain applicable insurance coverage for its officers, general liability insurance, and product liability insurance at levels deemed adequate by the Company’s Board of Directors. XenaCare cannot guarantee that these same levels of insurance, at premiums acceptable to the Company, will be available in the future. As related to product liability insurance, a reduction in coverage or exclusion for one or more key raw materials, may adversely affect our ability to continue our business as currently conducted. In addition, a loss of one or more of any of these insurance policies, or a claim-related loss in excess of insured limits might adversely affect our ability to continue our business as it is currently structured. Although we currently maintain $10,000,000 liability and medical expenses and $2,000,000 general aggregate ($5,000 deductible per occurrence) in the event that we become liable, there can be no assurance that our current insurance policy will be adequate to cover any such liabilities.
Like other distributors of nutrition supplements, we face an inherent risk of exposure to product liability claims in the event that the use of the products that we sell results in injury.
While management believes we are fully compliant with DSHEA, we may be subjected to various product liability claims, including claims that the NSPs we sell contain contaminants, are improperly labeled or include inadequate instructions as to use or inadequate warnings concerning side effects and interactions with other substances. In addition, we may be forced to defend lawsuits. While to date we have never been subject to any product liability claim, we cannot predict whether product liability claims will be brought against us in the future or the effect of any resulting adverse publicity on our business. Moreover, we may not have adequate resources in the event of a successful claim against us. Although we select our third party vendors, in part, on the fact that they themselves carry insurance against liability claims, we do not have formal indemnification arrangements with the third-party vendors from which we source our NSPs. If our insurance protection is inadequate and our third-party vendors do not indemnify us, the successful assertion of product liability claims against us could result in potentially significant monetary damages. In addition, interactions of our NSPs with other similar products, prescription medicines and over-the-counter drugs have not been fully explored. While XenaCare makes no labeling claims with its NSPs, because we will be dealing with large numbers of end users and will have a significant level of legal exposure due to this volume of customer relationships. The most serious area of exposure will be in relation to product advertising claims and the product quality. People may purchase NSPs from us expecting certain physical results, unique to nutrition products. If they do not perceive expected results to occur, certain individuals or groups of individuals may seek monetary retribution. We have no assurance that our insurance company will comply with coverage in all instances or that such coverage will be adequate to cover all potential losses.
Our business may be adversely affected by unfavorable publicity within the nutrition supplement market.
We believe that the nutrition supplement market is significantly affected by national media attention. As with any retail provider, future scientific research or publicity may not be favorable to the nutrition supplement industry or to any particular product, and may not be consistent with earlier favorable research or publicity. Because of our dependence on consumers’ perceptions, adverse publicity associated with illness or other adverse effects resulting from the consumption of our NSPs, personal performance or any similar products distributed by other companies and future reports of research that are perceived as less favorable or that question earlier research, could have a material adverse effect on our business, financial condition and results of operations. We are highly dependent upon consumers’ perceptions of the safety and quality of our products as well as similar products distributed by other companies. Thus, the mere publication of reports asserting that nutrition supplements or personal performance products may be harmful or questioning their efficacy could have a material adverse effect on our business, financial condition and results of operations, regardless of whether such reports are scientifically supported or whether the claimed harmful effects would be present at the dosages recommended for such products.
8
We are reliant on a limited number of products to generate revenues.
We currently offer a limited number of products. If we are unable to increase the number of products we offer, the risks associated with our business will increase since a decline in market demand for one or more products, for any reason, could have a significant adverse impact on the results of our operations.
Our success is dependent upon the successful introduction of our new products and success in expanding the demand for existing brands.
We believe the growth of our net sales is substantially dependent upon our ability to introduce our products to the public. At present, we have limited resources to spend on advertising and marketing therefore we will rely, to a large extent, on our agreements with strategic partners to assist in our development of distribution channels. Our ability to meet future obligations is dependent in large measure on the success of our product sales. We expect to introduce additional products. The success of new products is dependent upon a number of factors, including our ability to formulate products that will appeal to consumers and respond to market trends in a timely manner. There can be no assurance that our efforts to formulate new products will be successful or that consumers will accept our new products. In addition, products experiencing strong popularity and rapid growth may not maintain their sales volumes over time.
If our outside suppliers and manufacturers fail to supply products in sufficient quantities and in a timely fashion, our business could suffer.
Outside manufacturers and suppliers make and supply all of our products. We do not have long-term agreements with our manufacturers or suppliers. Our profit margins and timely product delivery are dependent upon the ability of our outside suppliers and manufacturers to supply us with products in a timely and cost-efficient manner. Our ability to enter new markets and sustain satisfactory levels of sales in each market depends upon the ability of our outside suppliers and manufacturers to produce the ingredients and products and to comply with all applicable regulations. As a precaution, we have approved alternate suppliers and manufacturers for our products. We believe we have dependable suppliers for all of our ingredients. If our suppliers are unable to perform, any delay in replacing or substituting such ingredients could affect our business. However, the failure of our primary suppliers or manufacturers to supply ingredients or produce our products could adversely affect our business operations.
We do not have long-term contracts with suppliers, manufacturers and distributors and we are dependent on the services of these third parties.
We purchase all of our products from third-party suppliers and manufacturers pursuant to purchase orders, but without any long-term agreements. In the event that a current supplier or manufacturer is unable to meet our manufacturing and delivery requirements at some time in the future, we may suffer short-term interruptions of delivery of certain products while we establish an alternative source. While we believe alternative sources are in most cases readily available and we have also established working relationships with several third-party suppliers and manufacturers, none of these agreements are long term. We also rely on third-party carriers for product shipments, including shipments to and from our distribution facilities. We are therefore subject to the risks, including employee strikes and inclement weather, associated with our carrier’s ability to provide delivery services to meet our fulfillment and shipping needs. Failure to deliver products to our customers in a timely and accurate manner would harm our reputation and our business and results of operations.
Many of our competitors have substantially greater financial, technical and human resources than we do.
We do not engage in research and development. Our competitors may succeed in formulating products that are more effective than those currently marketed or proposed for formulation by us. Progress by other researchers in areas similar to those being explored by us may result in further competitive challenges. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products. They may also establish exclusive collaborative or licensing relationships with our competitors.
In addition, large pharmaceutical companies have begun to compete with others and with us in the supplement industry. Packaged food and beverage companies compete with us on a limited basis in the supplement market. Increased competition from such companies could have a material adverse effect on us because such companies have greater financial and other resources available to them and possess manufacturing, distribution and marketing capabilities far greater than ours. We also face competition in both the health food store and mass market
9
distribution channels from private label nutrition supplements and multivitamins offered by health and natural food store chains, drugstore chains, mass merchandisers and supermarket chains.
ITEM 2
PROPERTIES.
In March 2010, the Company entered into a 3 year lease agreement for its new corporate headquarters at 6001 Broken Sound Parkway, Suite 630, Boca Raton, Florida 33487. The Company occupied the new facility in June 2010. The lease provides for the first fourth months of rent waived. The Company paid $8,296 in rent during 2010. This space is adequate to maintain and expand our business operations.
ITEM 3
There are currently no material legal proceedings, nor pending legal proceedings involving our Company.
ITEM 4
10
ITEM 5
MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
The Company’s common stock has been quoted on the Over-the-Counter Bulletin Board under the symbol “XCHO” since April 8, 2008. The Company’s high and low bid prices by quarter during 2010, as provided by the Over the Counter Bulletin Board are provided below. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not necessarily represent actual transactions. On March 14, 2011, the closing price of our common stock, as reported on the Over-the-Counter Bulletin Board, was $0.05 per share.
|
|
|
|
|
|
| Calendar Year 2010 |
| |
|
| High Bid | Low Bid |
|
| First Quarter | $0.50 | $0.089 |
|
| Second Quarter | $0.44 | $0.14 |
|
| Third Quarter | $0.29 | $0.0139 |
|
| Fourth Quarter | $0.17 | $0.05 |
|
|
|
|
|
|
| Calendar Year 2009 | |
| High Bid | Low Bid |
First Quarter | $0.25 | $0.02 |
Second Quarter | $0.32 | $0.045 |
Third Quarter | $0.24 | $0.0111 |
Fourth Quarter | $0.14 | $0.08 |
Transfer Agent and Registrar
The transfer agent for our common stock is. Pacific Stock Transfer Company, 4045 S. Spencer Street, Suite 403, Las Vegas, Nevada, 89919.
Number of Stockholders
As of January 20, 2011, there were approximately 119 shareholders of record.
Equity Compensation Plans
As of December 31, 2010, there were no equity compensation plans under which our securities are authorized for issuance.
Dividend Policy
We have not paid a dividend since incorporation and we do not anticipate paying any dividends in the future. We intend to retain earnings to finance the expansion of our business and for general working capital purposes. The Board of Directors may, however, determine whether we will pay dividends, depending on our earnings, financial condition, capital requirements, level of indebtedness, contractual restrictions with respect to the payment of dividends and other relevant factors. No assurance is given as to our ability or willingness to pay dividends in the future.
Recent Sales of Unregistered Securities
Preferred Stock
During the first quarter of 2010, we issued 191,141 shares of Series E Preferred Stock totaling $1,883,305 as follows:
·
56,502 shares totaling $536,918 were issued to satisfy all accrued and unpaid compensation and benefits for two consultants, one who provided acquisition and financing services and one who provided administration services. There services were terminated in 2009 and no new agreements were entered into with these individuals.
11
·
100,000 shares totaling $1,000,000 were issued to satisfy $1,000,000 of outstanding debt.
·
34,639 shares totaling $346,387 were issued to two employees (the CFO and the President) who are lenders to the Company to satisfy $346,387 of their outstanding debt.
No broker dealer was involved in the sale of the shares and no commission or other remuneration was paid in connection with the sale. The shares were issued in a private placement to an accredited investor pursuant to an exemption from registration under the Securities Act of 1933 pursuant to Section 4(2) thereof and Rule 506 of Regulation D. The shareholder who received the forgoing shares signed a subscription agreement acknowledging that the shares were not registered under the Securities Act of 1933, and could only be sold under a registration or exemption from registration. Each certificate for such shares contains a restricted legend concerning the foregoing restrictions on transfer and a stop transfer order has been lodged against such shares. The investor was offered access to our books and records and the opportunity to ask our officers questions and receive answers concerning the terms and condition of the offering and the company.
Common Stock
During the first quarter of 2010, 4,000,000 of outstanding warrants were exercised and exchanged for common shares. The warrants were originally granted in connection with a private stock sale in Q3 2009 to a qualified investor.
During the third quarter of 2010, we issued 1,600,000 shares of common stock totaling $202,400 as follows:
·
1,000,000 shares totaling $120,000 were issued to a consultant who provided funding services, which were subsequently cancelled and returned to treasury in Q1 2011.
·
500,000 shares totaling $60,000 were issued to a consultant who provided marketing services.
·
100,000 shares totaling $22,400 were issued to a consultant who provided investor relations services.
Also during the third quarter of 2010, we also sold 312,500 shares of common stock for $50,000 to an accredited investor. The shares were issued pursuant to an exemption from registration under the Securities Act of 1933 pursuant to Section 4(2) thereof. The shareholders who received the forgoing shares signed an investment letter acknowledging that the shares were not registered under the Securities Act of 1933, and could only be sold under a registration or exemption from registration. Each certificate for such shares contains a restricted legend concerning the foregoing restrictions on transfer and a stop transfer order has been lodged against such shares.
During the fourth quarter of 2010, we issued 1,170,662 shares of common stock totaling $94,018 as follows:
·
1,000,000 shares totaling $80,000 were issued to a consultant who provided operational services regarding the launching of EstraPet products.
·
45,662 shares totaling $4,018 were issued to a consultant who provided funding services, which were subsequently cancelled and returned to treasury in Q1 2011.
·
125,000 shares totaling $10,000 were issued to a consultant who provided funding services.
Warrants
During the fourth quarter of 2010, we issued 229,734 of warrants to purchase common stock. The warrants were issued in connection with obtaining financing from certain related parties. The warrants vest immediately and are valid for 5 years. The warrants are cashless, fully paid and non-assessable. The warrants were recorded as debt discount, at their fair value of $57,342 using the Black-Scholes-Merton pricing model.
ITEM 6
SELECTED FINANCIAL DATA.
Information not required by smaller reporting company.
12
ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing in this Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should review the “Risk Factors” section of this Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Caution Concerning Forward-Looking Statements
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This document contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, particularly statements anticipating future growth in revenues, operating income and cash flow. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “will,” “estimates,” and similar expressions are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, history of operating losses and accumulated deficit; possible need for additional financing; competition; dependence on management; risks related to proprietary rights; government regulation; and other factors discussed in this report and our other filings with the SEC.
Critical Accounting Policies and Estimates
Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Note 2 of the Notes to Consolidated Financial Statements describe the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.
A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: 1) we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and 2) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.
Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. Based on a critical assessment of our accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that our consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the United States, and present a meaningful presentation of our financial condition and results of operations. We believe the following critical accounting policies reflect our more significant estimates and assumptions used in the preparation of our consolidated financial statements:
Going Concern -- As shown in the accompanying financial statements, the Company’s operating and capital requirements in connection with operations have been and will continue to be significant. The recurring losses from operations and increased contractual agreements raise doubt about the Company’s ability to continue as a going concern. Based on current plans, the Company anticipates that revenues earned from Cobroxin™ product sales will be the primary source of funds for operating activities. In addition to existing cash, the Company may rely on bank borrowing, if available, or sales of securities to meet the basic capital and liquidity needs for the next 12
13
months. Additional capital may be sought to fund the expansion of product lines and marketing efforts, which may also include bank borrowing, or a private placement of securities. Our ability to continue as a going concern is dependent upon our ability to generate sales from our new products and our obtaining adequate capital to fund losses until we become profitable. There can be no assurance that management’s plans will be successful.
Our registered independent certified public accountants have stated in their report dated April 15, 2011 that we have incurred operating losses in the last two years, and have a significant working capital deficit. These factors among others may raise substantial doubt about our ability to continue as a going concern.
The financial statements have been prepared on a “going concern” basis and accordingly do not include any adjustments that might result from the outcome of this uncertainty.
Accounts Receivables -- Accounts receivable are reported at net realizable value. The Company establishes an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written-off when it is determined that the amounts are uncollectible.
Inventory – Inventory is reported at the lower end of cost or market on the first-in, first-out (FIFO) method. Our inventory is subject to expiration and accordingly quantities purchased and sell through rates are periodically monitored for potential overstocking or pending expiration as a basis for establishing the appropriate reserve for any estimated expiration or obsolescence. The Company’s principal brands are XenaCor, XenaTri, XenaZyme and its newest product line, Cobroxin™ .
Revenue Recognition -- The Company’s product revenues represent primarily sales of, XenaCor, XenaTri, XenaZyme and Cobroxin™. Revenue is recognized when a product is shipped. Product is not shipped until check or credit card payment is received from the customer. The Company manages the collection process for transactions processed on its website, but it outsources its fulfillment (delivery) process to a third party for certain products.
The Company’s revenue recognition policies are in compliance with SAB 104, Revenue Recognition, which establishes criteria that must be satisfied before revenue is realized or realizable and earned. The Company recognizes revenue when all of the following four criteria are met:
·
persuasive evidence of a sales arrangement exists,
·
delivery has occurred,
·
the sales price is fixed or determinable, and
·
collectability is probable.
Shipping and handling charges related to sales transactions are recorded as sales revenues when billed to customers or included in the sales price in accordance with ASC Topic 605, shipping and handling costs are included in cost of revenue.
The Company accepts product returns and will issue a credit, refund or product exchange. To date, product returns have occurred but are not considered material. The Company does not have a product return reserve established.
Recent Accounting Pronouncements
Recent accounting pronouncements that the Company has adopted or that will be required to adopt in the future are summarized below.
Accounting for uncertainty in income taxes - In September 2009, the FASB issued ASU 2009-06, Income Taxes (Topic 740), ”Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities”, which provides implementation guidance on accounting for uncertainty in income taxes, as well as eliminates certain disclosure requirements for nonpublic entities. The adoption of this standard did not have an impact on the Company’s consolidated financial position and results of operations since this accounting standard update provides only implementation and disclosure amendments..
In April 2010, the FASB issued ASU 2010-12. “Income Taxes” (Topic 740). ASU 2010-12 amends FASB Accounting Standard Codification subtopic 740-10 Income Taxes to include paragraph 740-10-S99-4. On March 30, 2010 The President signed the Health Care & Education Affordable Care Act reconciliation bill that amends its
14
previous Act signed on March 23, 2010. FASB Codification topic 740, Income Taxes, requires the measurement of current and deferred tax liabilities and assets to be based on provisions of enacted tax law. The adoption of this standard did not have a material impact on the Company’s consolidated financial position and results of operations.
Fair value measurements - In January 2010, the FASB has published ASU 2010-06 “Fair Value Measurements and Disclosures (Topic 820): - Improving Disclosures about Fair Value Measurements. ASU No. 2010-06 clarifies improve disclosure requirement related to fair value measurements and disclosures – Overall Subtopic (Subtopic 820-10) of the FASB Accounting Standards Codification. The adoption of this standard did not have a material impact on the Company’s consolidated financial position and results of operations.
Accounting for Stock Compensation - In April 2010, the FASB issued ASU 2010-13 “Stock Compensation” (Topic 718). ASU 2010-13 provides amendments to Topic 718 to clarify that an employee share-based payment award with an exercise price denominated in the currency of a market in which a substantial portion of the entity's equity securities trades should not be considered to contain a condition that is not a market, performance, or service condition. Therefore, an entity would not classify such an award as a liability if it otherwise qualifies as equity. The adoption of this standard did not have any impact on the Company’s consolidated financial position and results of operations.
Intangibles – Goodwill and Other - In December 2010, the FASB issued ASU No. 2010-28 “Intangibles – Goodwill and Other (Topic 350).” ASU No. 2010-28 addresses questions about entities with reporting units with zero or negative carrying amounts because some entities concluded that Step 1 of the goodwill impairment test, as stated in Topic 350, is passed in those circumstances because the fair value of their reporting unit will generally be greater than zero. The amendments in this update do not provide guidance on how to determine the carrying amount or measure the fair value of the reporting unit. The amendments in this update modify Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. The Company is evaluating the impact ASU No. 2010-28 will have on the consolidated financial statements.
Business Combinations - In December 2010, the FASB issued ASU No. 2010-29 “Business Combinations (Topic 805).” ASU No. 2010-29 addresses the diversity in practice about the interpretation of the pro forma revenue and earnings disclosure requirements for business combinations. The amendments in this update specify that if a public entity presents comparative financial statements, the entity should disclose revenue and earnings of the combined entity as though the business combination(s) that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. The amendments in this update also expand the supplemental pro forma disclosures under Topic 805 to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings. The Company is evaluating the impact ASU No. 2010-29 will have on the consolidated financial statements.
RESULTS OF OPERATIONS
The following discussion and analysis addresses the major factors that affected our operations and financial condition reflected in our consolidated audited financial statements for the years ended December 31, 2010 and December 31, 2009. This discussion is intended to supplement and highlight information contained in, and should be read in conjunction with, our financial statements and related notes and the selected financial data presented elsewhere in this report.
Results of Operations for the year ended December 31, 2010 as compared to the year ended December 31, 2009
Year Ended December 31, 2010 (“2010-YTD”) to the Year Ended December 31, 2009 (“2009-YTD”)
Revenues, net - Net revenues increased $1,786,854 or 908.9%, to $1,983,497 for 2010-YTD from $196,603 for 2009-YTD. Most of our revenues in 2010 were generated from Cobroxin whereas in 2009 were generated by our proprietary SunPill and Clinical NSPs - XenaCor, XenaTri and XenaZymePlus. We have shifted our resources committed to achieving this product focus over the last 30 months, which has had a direct impact on our revenues in 2010. Although we will continue to market our Clinical NSPs, after redirecting our efforts and allocating available resources to concentrate on the distribution of the Cobroxin during 2010, we have decided to discontinue promoting SunPill due to market challenges encountered.
15
During the second quarter of 2009 we began to focus on the sale of Cobroxin as a result of being awarded the US marketing rights from Nutra Pharma, Inc on May 26, 2009. Cobroxin is the first over-the-counter pain reliever clinically proven to treat chronic pain. Cobroxin is available as an oral spray for lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, and as a topical gel for repetitive stress, arthritis and joint pain. Cobroxin is a derivative of cobra venom, is all-natural, non-addictive, non-narcotic, non-opiate, long lasting and in some clinical tests proven to be more effective than morphine. Internet sales of Cobroxin began in the fourth quarter of 2009 with retail distribution commencing in the first quarter of 2010.
Cost of Revenue - Total cost of revenues decreased $849,594 or 4,101.1%, to $870,310 for 2010-YTD from $20,716 for 2009-YTD. The increase in costs of revenue is primarily related to increased sales of Cobroxin as a result of establishing our primary product focus on Cobroxin and promoting and developing it as a commercialized product.
Selling and Marketing Costs - Selling and marketing costs increased $1,683,000 or 176.1%, to $2,568,186 for 2010-YTD from $930,186 2009-YTD. The increase in selling and marketing expenses is primarily due to increased in advertising and promotional efforts related to the introduction of Cobroxin.
General and Administrative Costs - General and administrative costs decreased $180,918 or 15.1%, to $1,015,425 for 2010-YTD from $1,196,343 for 2009-YTD. The decrease is considered nominal and reflects maintenance of the 2009 cost structure.
Impairment and Write Down – Impairment expense increased $627,236 or 6,272.4%, to $637,236 for 2010-YTD from $10,000 for 2009-YTD. The increase is primarily due to write off of the SunPill inventory along with certain trade credits.
Other Income (Expense) - Other expenses decreased $51,273 or 15.5% to $280,529 expense for 2010-YTD from $331,802 expense for 2009-YTD. The decrease was primarily a result of a $144,815 decrease in other expenses due to charges in 2009-YTD which did not repeat in 2010-YTD, which was partially offset by a $79,180 increase in interest expense associated with expanded borrowings.
Liquidity and Capital Resources
We incurred a net loss for the year ended December 31, 2010 and 2009 of $3,388,189 and $2,292,444 respectively resulting in accumulated deficits of $12,758,413 and $9,370,224, respectively. We had a $2,918,778 deficit in working capital at December 31, 2010 compared to a $2,042,682 deficit in working capital at December 31, 2009. Although we believe our retail distribution launch of our Cobroxin product in the first quarter of 2010 will establish an ongoing source of revenues sufficient to cover our operating costs, in 2010 our commitment to marketing and advertising efforts in launching Cobroxin as well as funding increased required inventories offset the increased revenue. We successfully raised approximately $2.6 million in debt and equity offerings to implement our business model however we cannot assure that continued financing will be available should the Cobroxin commercialization and associated operations require additional capital. Our ability to continue as a going concern is dependent upon our ability to generate sales from our new products and our obtaining adequate capital to fund losses until we become profitable.
In addition to existing cash and cash equivalents, we may rely on bank borrowing, if available, or sales of securities to meet the basic capital and liquidity needs for the next 12 months. Additional capital may be sought to fund the expansion of our product line and marketing efforts, which may also include bank borrowing, or a private placement of securities.
While we have been able to manage our working capital needs with the current credit facilities, additional financing is required in order to meet our current and projected cash flow requirements from operations. We cannot predict whether this new financing will be in the form of equity or debt. We may not be able to obtain the necessary additional capital on a timely basis, on acceptable terms, or at all. Additional investments are being sought, but we cannot guarantee that we will be able to obtain such investments. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. However, the trading price of our common stock and the downturn in the U.S. stock and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue
16
additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.
Our registered independent certified public accountants have stated in their report dated April 15, 2011 that we have incurred operating losses in the past years, and that we are dependent upon management’s ability to develop profitable operations and/or obtain necessary funding from outside sources, including by the sale of our securities, or obtaining loans from financial institutions, where possible. These factors, among others, may raise substantial doubt about our ability to continue as a going concern.
Cash Flows for the Year Ended December 31, 2010
Cash Flows from Operating Activities
Operating activities used net cash for the year ended December 31, 2010 of $2,775,613. Net cash used reflects an adjusted net loss for the period ended of approximately $2,475,080 as adjusted for various items which impact net income but do not impact cash during the period, such as depreciation and amortization and stock issued for services. Net cash used also reflects $300,532 of cash used by net changes in working capital items, which included:
·
a $132,057 increase in accounts receivable as a result of increased Cobroxin sales;
·
a $505,614 increase in inventory also due to increased Cobroxin sales;
·
a $132,150 increase in prepaid and other current assets, primarily as a result of the addition of several prepaid consulting arrangements;
·
a $469,289 increase in accounts payable and accrued expenses as a result of increased supplier financing for materials.
Cash Flows used in Investing Activities
Investing activities used $50,472 cash primarily as a result of increased rent deposits and other assets.
Cash Flows from Financing Activities
Our financing activities provided net cash of $2,611,581 for the year ended December 31, 2010, of which $2,748,869 was raised through the issuance of notes as described in Notes 8 and 10 to the audited financial statements. In addition the Company raised $50,000 from a qualified investor, the issuance of equity.
Contractual Obligations
The following table summarizes our significant contractual obligations as of December 31, 2010:
|
| Payments Due by Period |
| |||||||||||||
Category |
| Total |
| Less Than 1 Year |
| 1-3 Years |
| 3-5 Years |
| More Than 5 Years |
| |||||
Operating lease obligations (1) |
| $ | 90,312 |
| $ | 35,189 |
| $ | 55,123 |
| $ | — |
| $ | — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital purchase obligations (2) |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other purchase obligations and commitments (3) |
|
| 5,000,000 |
|
| 1,000,000 |
|
| 3,000,000 |
|
| 1,000,000 |
|
| — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt obligations (4) |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities (5) |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
|
| $ | 5,090,312 |
| $ | 1,035,189 |
| $ | 3,055,123 |
| $ | 1,000,000 |
| $ | — |
|
———————
(1)
In March 2010, the Company entered into a 3 year lease agreement for its new corporate headquarters in Boca Raton, Florida. The Company occupied the new facility in June 2010. The lease provides for the first four months of rent waived.
(2)
We have no commitments for the future construction or purchase of property, plant and equipment.
17
(3)
Our exclusive distribution agreement was modified March 15, 2010 with the manufacturer of our Cobroxin product provides that we are committed to purchase approximately $250,000 of product per quarter for the term of the agreement, in order to maintain our exclusivity.
(4)
We have no long-term debt commitments at December 31, 2010.
(5)
We have no other long-term debt commitments at December 31, 2010, such as expected contributions to pension or post retirement benefit plans or other contractual obligations not recorded in our books
Inflation
We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could adversely affect our business, financial condition and results of operations.
Off Balance Sheet Arrangements
We do not maintain off-balance sheet arrangements nor does it participate in any non-exchange traded contracts requiring fair value accounting treatment.
ITEM 7A
QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
Disclosure not required by small reporting company.
ITEM 8
FINANCIAL STATEMENTS
See the consolidated financial statements commencing on page F-1
ITEM 9
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
Previous independent registered public accounting firm
On February 20, 2011 (the “Resignation Date”), Jewett, Schwartz, Wolfe & Associates (“JSW”) advised Xenacare Holdings, Inc. (the “Company”) that its audit practice was acquired by RBSM LLP (“RBSM ”), an independent registered public accounting firm and that, accordingly, JSW was resigning as the Company’s independent registered public accounting firm. The Company’s Board of Directors did not recommend or approve the resignation of JSW as the Company’s independent registered public accounting firm.
The reports of JSW on the Company’s financial statements for the years ended December 31, 2009 and 2008 did not contain an adverse opinion or disclaimer of opinion, and such reports were not qualified or modified as to uncertainty, audit scope, or accounting principle, except that the reports of JSW on the Company’s consolidated financial statements as of and for the years ended December 31, 2009 and 2008 contained an explanatory paragraph which noted that there was substantial doubt as to the Company’s ability to continue as a going concern due to a deficit in working capital and incurring significant losses.
In connection with the audits of the Company’s financial statements for each of the fiscal years ended December 31, 2009 and 2008 and through the date of this Current Report, the Company has not had any disagreements with JSW on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to JSW’s satisfaction, would have caused them to make reference thereto in their reports on the Company’s financial statements for such periods.
During the Company’s two most recent fiscal years and through the date of this Current Report, there were no reportable events, as defined in Item 304(a)(1)(v) of Regulation S-K.
New independent registered public accounting firm
On February 20, 2011 (the “Engagement Date”), the Company engaged RBSM LLP (“RBSM ”) as its independent registered public accounting firm for the Company’s fiscal year ended December 31, 2010. The engagement of RBSM as the Company’s independent registered public accounting firm was approved by the Company’s Board of Directors.
18
ITEM 9A
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “ SEC”), and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.
The Company’s management, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial (and principal accounting) Officer, carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act) as of December 31, 2010. Based upon that evaluation and the identification of the material weakness in the Company’s internal control over financial reporting as described below under “Management’s Report on Internal Control over Financial Reporting,” the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were ineffective as of the end of the period covered by this report.
Evaluation of and Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting of the Company. Management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our internal control over financial reporting as of December 31, 2009 based on the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, because of the Company’s limited resources and limited number of employees, management concluded that, as of December 31, 2009, our internal control over financial reporting is not effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.
To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.
This annual report does not include an attestation report of the company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the company's registered public accounting firm pursuant to temporary rules of the SEC that permit the company to provide only management's report in this annual report.
Limitations on Effectiveness of Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
19
Changes in Internal Control Over Financial Reporting
There were no changes in the Company’s internal control over financial reporting during the fourth quarter of fiscal 2010, which were identified in connection with management’s evaluation required by paragraph (d) of rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
ITEM 9B
OTHER INFORMATION
The Company received a letter from counsel for Nutra Pharma Corp. terminating its distribution agreement for Cobroxin effective April 10, 2011. The Company does not believe that such termination was valid and intends to vigorously pursue its rights in this matter.
20
ITEM 10
DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE
Our articles of incorporation permit our board of directors to fix the number of directors at not less than one or more than seven. Directors serve until our next annual meeting of shareholders and until his successor is duly elected and qualified. Vacancies on the Board due to resignation or removal may be filled by the remaining director or directors, even though less than a quorum, for the unexpired term of such vacant position. Officers may be removed by the Board at any time.
Our directors and officers are:
Name |
| Age |
| Current Position |
Frank Rizzo |
| 56 |
| President/CEO and Chairman/ Director |
Bobby Story |
| 69 |
| Chief Financial officer and Director |
Dr. Alan Xenakis |
| 61 |
| Director |
Frank Rizzo has served as an officer and director and Vice President of the Company from its inception through February 1, 2006. In February he was promoted to President. From 1993 through 2005, Mr. Rizzo served as president of Momentum Marketing, Inc., a financial and marketing company based in Tampa, Florida. Mr. Rizzo owned a private building materials company from September 1984 through December 1990. He worked from 1977 through 1983 in Regional and National Marketing with a Fortune 500 Company. Mr. Rizzo attended Adelphi University and New York Institute of Technology. He holds a B.S. in management and marketing from the New York Institute of Technology. The Company believes Mr. Rizzo’s past experience in marketing gives him the qualifications and skill to serve as a Director.
Bobby Story has served as our chief financial officer and director since April 2006. From 1970 through 1972 Mr. Story practiced as a certified public accountant. He was employed by Arthur Young & Company, CPA (now known as Ernst & Young, LLP) from 1970 through 1972. He served as treasurer for Condev Corporation, an international developer based in Winter Park, Florida from 1972 to 1975. From 1975 to 1981 he served as Director of Real Estate Operations for Drexel Burnham Lambert and Company. From 1982 to 1987 Mr. Story was self employed, providing financial advisory services to several companies. From April 1987 to March 1996 he served as controller and vice president of finance for NACEX, Inc. From October 1996 to October 2000 he served as CFO of American Access Technologies, Inc. From February 2001 through October 2001 he served as chief financial officer for iBid America, Inc., which was acquired by Interactive Brand Development, Inc. (OTCBB: IBDI). Since October 2001 Mr. Story has provided financial consulting services to several companies including but not limited to Interactive Brand Development, Inc. The Company believes Mr.Story’s past experience in corporate finance and compliance gives him the qualifications and skill to serve as a Director.
Dr. Alan Xenakis has served as a director of the Company since its inception and served as a director of XenaCare LLC since its inception. Since the founding of XenaCare LLC in 2001, Dr. Xenakis has acted as its chief operating officer and medical director. In addition, from 1999 to 2000, Dr. Xenakis served as vice president of Global Health Sciences, a company principally engaged in the manufacture of Nutraceuticals, which was acquired by Nature’s Bounty in 2001. Dr. Xenakis was involved in a bankruptcy associated with his divorce in 1999. The bankruptcy was discharged without prejudice in August of 1999. Dr. Xenakis has been a member of Leadership Broward since 2002. He holds a B.S. in chemistry from the University of New Hampshire, a M.S. in health dynamics from Boston University and received his medical degree from Boston University School of Medicine. Dr. Xenakis also holds a Doctor of Science from Boston University and a Master of Public Health from Harvard University. We took into account his prior work in the healthcare products industry and believe Dr.Xenakis’s past experience in these fields gives him the qualifications and skill to serve as a Director.
Board of Directors
The board of directors met 11 times during 2010. Each director attended at least 75% of these meetings.
Committees of the Board of Directors
We plan to establish an Audit Committee, Compensation Committee and a Nominating and Governance Committee. Until such committees are established, matters otherwise addressed by such committees will be acted
21
upon by the majority of the current Board of Directors. The entire board of directors acts as our audit committee as permitted under Section 3(a) (58) (B) of the Exchange Act. We believe that it has been, and may continue to be, impractical to recruit independent directors unless and until we are significantly larger.
Code of Ethics
The Company has adopted a Code of Ethics which is filed as Exhibit 14 to this Annual Report. This policy is applicable to all of the Company’s directors, officers and employees, including its principal executive officer, principal financial officer and principal accounting officer. We will provide a copy to any person, without charge, upon a request in writing to: Frank Rizzo, President, XenaCare Holdings, Inc., 6001 Broken Sound Parkway, Suite 630 Boca Raton, Florida 33487.
ITEM 11
EXECUTIVE COMPENSATION
Executive Compensation
The following table shows, for the years ended December 31, 2010 and December 31, 2009, compensation information for our Named Executive Officers.
Summary Compensation Table
|
|
|
|
|
| Stock Awards |
|
|
| All Other Compensation |
|
|
|
Name and Position |
| Year |
| Salary |
|
| Options |
|
| Total |
| ||
Frank Rizzo |
| 2009(1) |
| $200,000 |
| — |
| — |
| $25,000 |
| $225,000 |
|
President |
| 2010(1) |
| $180,000 |
| — |
| — |
| $25,000 |
| $205,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bobby Story |
| 2009(2) |
| $200,000 |
| — |
| — |
| $25,000 |
| $225,000 |
|
CFO |
| 2010 |
| $180,000 |
| — |
| — |
| $25,000 |
| $205,000 |
|
———————
(1)
Mr. Rizzo in the first quarter of 2010 converted his accrued compensation and medical insurance allowance for 2008 and 2009 into Series E. Preferred Stock of the Company.
(2)
Mr. Story in the first quarter of 2010 converted his accrued compensation and medical insurance allowance for 2008 and 2009 into Series E Preferred Stock of the Company.
Outstanding Equity Awards at Fiscal Year End
We have not granted any equity compensation in the year ended December 31, 2010 and no such awards are outstanding as of December 31, 2010.
Director Compensation
None of our directors receive an annual fee for services. We do not pay fees to directors for their attendance at meetings; however, we may adopt a policy of making such payments in the future. We will reimburse out-of-pocket expenses incurred by directors in attending Board and committee meetings.
Employment and Consulting Agreements
While the Company had employment agreements approved by the Board of Directors with its Chief Executive Officer/President and CFO and they were compensated at a rate of approximately $225,000 per year. Mr. Rizzo and Mr. Story are eligible to receive and participate in all other benefit, bonus, retirement, insurance and long-term incentive programs provided by the Company for its senior executive personnel. In the event of Mr. Rizzo’s or Mr. Story’s termination (other than without cause by the Company) they have agreed to a 12-month non-compete provision. All compensation arising from these consulting agreements was accrued and unpaid for 2009 and 2010. Mr. Rizzo’s and Mr. Story’s employment agreements were terminated as of December 31, 2009 by mutual agreement. Accrued salaries for FY 2009 for both Mr. Rizzo and Mr. Story were converted to preferred stock.
22
ITEM 12
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
As of January 20, 2011, there were 76,825,434 shares of our common stock issued and outstanding. The following table sets forth, as of the close of business on March 31, 2011, (1) the name and number of shares of each person known by us to be the beneficial owner of more than 5% of our common stock; and (2) the number of shares of these securities beneficially owned by each director and executive officer and all of our executive officers and our directors as a group, together with their respective percentage holdings of such shares. Beneficial ownership is determined in accordance with the rules of the SEC, and generally includes voting or investment power with respect to securities, and includes any securities, which the person has the right to acquire within 60 days of the date of this table. Unless otherwise indicated, the address for each person is XenaCare Holdings, Inc., 6001 Broken Sound Parkway, Suite 630 Boca Raton, Florida 33487.
|
| Shares Beneficially Owned |
| ||
Name and Position of Beneficial Owner |
| Number |
| Percent |
|
Dr. Alan Xenakis, director |
| 6,832,686 |
| 9.38 % |
|
Frank Rizzo(1), CEO and director |
| 3,656,361 |
| 4.958 % |
|
Bobby Story(2), CFO and director |
| 100,000 |
| * |
|
Martin Hodas, shareholder |
| 12,500,000 |
| 16.95% |
|
|
|
|
|
|
|
All Directors and Officers as a group (3 persons) |
| 10,589,047 |
| 31.31 % |
|
———————
*
Less than 1%
(1)
Does not include shares of stock owned by adult family members or trusts for the benefit of minor family children as to which beneficial ownership is disclaimed. Does not include 30,234 shares of preferred stock that was issued for converting his past accrued salaries and benefits.
(2)
Does not include shares of stock owned by adult family members or trusts for the benefit of minor family children as to which beneficial ownership is disclaimed. Does not include 30,234 shares of preferred stock that was issued for converting his past accrued salaries and benefits.
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
As of March 31, 2011, approximately $1,850,000 is owed to a shareholder of the Company, relating to advances made by such shareholder, as follows:
Name
Amount
Martin Hodas
$1,850,000
Such funds accrue interest at various rates from 12% to 15% and mature in increments from February 2011 to July 2012.
The Company’s policy requires all related party transactions to be approved by a majority of the directors who have no interest in the transaction.
Director Independence
The following information concerning director independence is based on the director independence standards of The NASDAQ Stock Market Corporate Governance Rules.
The Board has determined that directors Dr. Alan Xenakis, Frank Rizzo and Bobby are not independent. In determining independence, the Board reviews and seeks to determine whether directors have any material relationship with the Company, direct or indirect, which would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Board reviews business, professional, charitable and familial relationships of the directors in determining independence.
The Board has not designated a separate compensation or nominating committee.
23
Audit Committee
The Board of Directors has not designated a separate audit committee and the entire Board, whose members are named above, conducts the functions of such committee. The Board has determined that Bobby Story is an audit committee financial expert and that Mr. Story is not an independent director.
ITEM 14.
PRINCIPAL ACCOUNTING FEES AND SERVICES
Fees to Auditors Fiscal Year ended December 31, 2010
Audit Fees: The aggregate fees, including expenses, billed by the Company's principal accountants for professional services rendered for the audit of the Company’s financial statements during the fiscal year ending December 31, 2010 and for the review of the Company’s financial information included in its quarterly reports on Form 10-Q during the fiscal year ending December 31, 2010 or services that are normally provided in connection with statutory and regulatory filings or engagements during the fiscal year ending December 31, 2010 was $ 41,500.
Audit Related Fees: The aggregate fees, including expenses, billed by principal accountants for assurance and related services reasonably related to the performance of the Company’s audit or review of the Company’s financial statements were $0.
Tax Fees: The aggregate fees, including expenses, billed by principal accountants for tax compliance, tax advice and tax planning during year 2010 was $0.
All Other Fees: The aggregate fees, including expenses, billed for all other services rendered to the Company by principal accountants during year 2010 was $0.
Fees to Auditors Fiscal Year ended December 31, 2009
Audit Fees: The aggregate fees, including expenses, billed by the Company's principal accountants for professional services rendered for the audit of the Company’s consolidated financial statements during the fiscal year ending December 31, 2009 and for the review of the Company’s financial information included in its quarterly reports on Form 10-Q during the fiscal year ending December 31, 2009 or services that are normally provided in connection with statutory and regulatory filings or engagements during the fiscal year ending December 31, 2009 was $59,500.
Audit Related Fees: The aggregate fees, including expenses, billed by principal accountants for assurance and related services reasonably related to the performance of the Company’s audit or review of the Company’s financial statements were $-0-.
Tax Fees: The aggregate fees, including expenses, billed by principal accountants for tax compliance, tax advice and tax planning during year 2009 was $545.
All Other Fees: The aggregate fees, including expenses, billed for all other services rendered to the Company by principal accountants during year 2009 was $28,725
Board of Directors Report
The Board of Directors has reviewed and discussed with the Company’s management and independent auditor the audited consolidated financial statements of the Company contained in the Company’s Annual Report on Form 10-K for the Company’s 2010 fiscal year. The Board has also discussed with the independent auditor the matters required to be discussed pursuant to SAS No. 61 (Codification of Statements on Auditing Standards, AU Section 380), which includes, among other items, matters related to the conduct of the audit of the Company’s consolidated financial statements.
The Board has received and reviewed the written disclosures and the letter from the independent auditor required by the applicable requirements of the Public Company Accounting Oversight Board regarding the independent auditor’s communications with the Board concerning independence, and has discussed with its independent auditor its independence from the Company.
The Board has considered whether the provision of services other than audit services is compatible with maintaining auditor independence.
24
Based on the review and discussions referred to above, the Board approved the inclusion of the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for its 2010 fiscal year for filing with the SEC.
Pre-Approval Policies
The Board’s policy is to pre-approve all audit services and all permitted non-audit services (including the fees and terms thereof) provided by the Company’s independent auditor; provided, however, pre-approval requirements for non-audit services are not required if all such services (1) do not aggregate to more than five percent of total revenues paid by the Company to its accountant in the fiscal year when services are provided; (2) were not recognized as non-audit services at the time of the engagement; and (3) are promptly brought to the attention of the Board and approved prior to the completion of the audit.
The Board pre-approved all fees described above.
25
ITEM 15
EXHIBITS, FINANCIAL STATEMENT SCHEDULE
No. |
| Description |
|
|
|
2.7 |
| Articles of Incorporation (Incorporated by reference to Exhibit 2.7 to registrant’s SB-2)* |
3.0 |
| Bylaws of the Company (Incorporated by reference to Form 14C)* |
10.1 |
| Employment Agreement with Frank Rizzo* |
10.2 |
| Employment Agreement with Bobby Story* |
10.3 |
| Distribution Agreement for Cobroxin (Incorporated by reference to Exhibit 10.16 to registrant’s Quarterly Report on Form 10-Q filed November 16, 2010)* |
10.4 |
| Preferred Stock Series E designations |
14 |
| Code of Ethics * |
21 |
| Subsidiaries |
31.1 |
| Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act. |
31.2 |
| Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act. |
32.1 |
| Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act. |
32.2 |
| Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act. |
———————
*
Denotes a management contract or compensatory plan or agreement.
26
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: April 15, 2011
| XENACARE HOLDINGS, INC. | |
|
|
|
|
|
|
| By: | /s/ Frank Rizzo |
|
| Frank Rizzo President/CEO |
Pursuant to the requirements of the Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature |
| Title |
| Date |
/s/ Frank Rizzo |
| President, Principal Executive Officer, Director |
| April 15, 2011 |
Frank Rizzo |
|
|
| |
|
|
|
|
|
/s/ Alan Xenakis |
| Director |
| April 15 2011 |
Alan Xenakis |
|
|
|
|
|
|
|
|
|
/s/ Bobby Story |
| Secretary, Principal Financial Officer, and Director |
| April 15, 2011 |
Bobby Story |
|
|
27
XENACARE HOLDINGS, INC.
FINANCIAL STATEMENTS
INDEX
Report of Independent Registered Public Accounting Firms |
| F-2 |
Consolidated Financial Statements: |
|
|
Consolidated Balance Sheets |
| F-4 |
Consolidated Statements of Operations |
| F-5 |
Consolidated Statements of Changes in Shareholders’ Deficit |
| F-6 |
Consolidated Statements of Cash Flows |
| F-7 |
Notes to Consolidated Financial Statements |
| F-8 |
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
XenaCare Holdings, Inc.
We have audited the accompanying consolidated balance sheet of XenaCare Holdings, Inc (“the Company”) as of December 31, 2010 and the related consolidated statements of operations, stockholders' deficit, and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have nor were we engaged to perform, an audit of its Internal Control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2010 and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1, the Company has incurred significant losses from operations since its inception and has a working capital deficiency. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ RBSM LLP
New York, NY
April 15, 2011
F-2
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
XenaCare Holdings, Inc.
We have audited the accompanying balance sheets of XenaCare Holdings, Inc. as of December 31, 2009 and the related statements of operations, changes in stockholders' deficit and cash flows for the years ended December 31, 2009. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of XenaCare Holdings, Inc. and Subsidiaries as of December 31, 2009 and the results of its operations and its cash flows for the years ended December 31, 2009 in conformity with accounting principles generally accepted in the United States of America.
These accompanying financial statements referred to above have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company's need, to seek new sources or methods of financing or revenue to pursue its business strategy, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans as to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/Jewell, Schwartz, Wolfe & Associates
Hollywood, Florida
April 14, 2010
F-3
XENACARE HOLDINGS, INC.
BALANCE SHEETS
|
| December 31, |
| December 31, |
| ||
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
|
Cash |
| $ | 10,515 |
| $ | 225,019 |
|
Accounts receivable |
|
| 127,254 |
|
| 30,002 |
|
Inventory |
|
| 970,696 |
|
| 829,318 |
|
Prepaid expenses and other current assets |
|
| 384,158 |
|
| 172,008 |
|
|
|
|
|
|
|
|
|
Total Current Assets |
|
| 1,492,623 |
|
| 1,256,347 |
|
|
|
|
|
|
|
|
|
Office Furniture and Equipment, net |
|
| 12,500 |
|
| — |
|
Other Assets |
|
| 35,472 |
|
| 273,000 |
|
|
|
|
|
|
|
|
|
TOTAL ASSETS |
| $ | 1,540,595 |
| $ | 1,529,347 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' DEFICIT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
| $ | 1,054,262 |
| $ | 1,121,889 |
|
Notes payable - current |
|
| 3,097,964 |
|
| 2,177,138 |
|
Revolving credit facility |
|
| 259,174 |
|
| — |
|
|
|
|
|
|
|
|
|
Total Current Liabilities |
|
| 4,411,400 |
|
| 3,299,028 |
|
|
|
|
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholder's Deficit |
|
|
|
|
|
|
|
Preferred stock, 5,000,000 shares authorized: |
|
|
|
|
|
|
|
Series E, $0.001 par value, 270,435 and 79,294 shares issued and outstanding at December 31, 2010 and December 31, 2009 |
|
| 270 |
|
| 79 |
|
Common stock, $0.001 par value, 200,000,000 shares authorized: |
|
|
|
|
|
|
|
76,825,434 and 69,742,272 shares issued and outstanding at December 31, 2010 and December 31, 2009, respectively |
|
| 76,825 |
|
| 69,742 |
|
Additional paid-in-capital |
|
| 9,810,513 |
|
| 7,530,722 |
|
Accumulated deficit |
|
| (12,758,413 | ) |
| (9,370,224 | ) |
|
|
|
|
|
|
|
|
Total Shareholders' Deficit |
|
| (2,870,805 | ) |
| (1,769,681 | ) |
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT |
| $ | 1,540,595 |
| $ | 1,529,347 |
|
See accompanying notes to consolidated financial statements.
F-4
XENACARE HOLDINGS, INC. AND SUBSIDIARIES
STATEMENTS OF OPERATIONS
|
| Year Ended December 31, |
| ||||
|
| 2010 |
| 2009 |
| ||
Revenue, net |
|
|
|
|
|
|
|
Product sales |
| $ | 2,783,399 |
| $ | 204,137 |
|
Less: Advertising and marketing allowances |
|
| (780,572 | ) |
| — |
|
Less: Returns and other allowances |
|
| (19,330 | ) |
| (7,534 | ) |
|
|
|
|
|
|
|
|
Total revenue, net |
|
| 1,983,497 |
|
| 196,603 |
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
| 870,310 |
|
| 20,716 |
|
|
|
|
|
|
|
|
|
Gross profit |
|
| 1,113,187 |
|
| 175,887 |
|
|
|
|
|
|
|
|
|
Operating costs and expenses: |
|
|
|
|
|
|
|
Selling and marketing |
|
| 2,568,186 |
|
| 930,186 |
|
General and administrative |
|
| 1,015,425 |
|
| 1,196,343 |
|
Write downs and asset impairment |
|
| 637,236 |
|
| 10,000 |
|
|
|
|
|
|
|
|
|
Total operating costs and expenses |
|
| 4,220,847 |
|
| 2,136,529 |
|
|
|
|
|
|
|
|
|
Loss from Operations |
|
| (3,107,660 | ) |
| (1,960,642 | ) |
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
|
Interest expense |
|
| (272,924 | ) |
| (193,744 | ) |
Other income |
|
| 1,281 |
|
| 15,643 |
|
Other expenses |
|
| (8,886 | ) |
| (153,701 | ) |
|
|
|
|
|
|
|
|
Total other income (expense) |
|
| (280,529 | ) |
| (331,802 | ) |
|
|
|
|
|
|
|
|
Net Loss |
| $ | (3,388,189 | ) | $ | (2,292,444 | ) |
|
|
|
|
|
|
|
|
Basic and Diluted: |
|
|
|
|
|
|
|
Weighted average shares |
|
| 73,941,404 |
|
| 53,938,034 |
|
Loss per share |
| $ | (0.05 | ) | $ | (0.04 | ) |
See accompanying notes to consolidated financial statements.
F-5
XENACARE HOLDINGS, INC.
STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT
FOR THE YEARS ENDED DECEMBER 31, 2010 AND 2009
|
|
|
|
|
|
|
|
|
| Additional |
| Accumulated |
| Total Deficit |
| |||||
Preferred Stock | Common Stock | |||||||||||||||||||
Shares |
| Amount | Shares |
| Amount | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2008 |
| 500,000 |
| $ | 500 |
| 43,026,695 |
| $ | 43,026 |
| $ | 5,984,396 |
| $ | (7,077,780 | ) | $ | (1,049,858 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange shares |
| — |
|
| — |
| 66,667 |
|
| 67 |
|
| (67 | ) |
| — |
|
| — |
|
Sale of shares |
| — |
|
| — |
| 12,500,000 |
|
| 12,500 |
|
| 487,500 |
|
| — |
|
| 500,000 |
|
Series E |
| 79,294 |
|
| 79 |
| — |
|
| — |
|
| 793,392 |
|
| — |
|
| 793,471 |
|
Series F |
| 2,632 |
|
| 3 |
| — |
|
| — |
|
| 263,147 |
|
| — |
|
| 263,150 |
|
Consulting services |
|
|
|
|
|
| 1,000,000 |
|
| 1,000 |
|
| 15,000 |
|
|
|
|
| 16,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares converted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A |
| (500,000 | ) |
| (500 | ) | 10,748,340 |
|
| 10,748 |
|
| (10,248 | ) |
| — |
|
| — |
|
Series F |
| (2,632 | ) |
| (3 | ) | 3,000,570 |
|
| 3,001 |
|
| (2,998 | ) |
| — |
|
| — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares cancelled |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange shares |
| — |
|
| — |
| (100,000 | ) |
| (100 | ) |
| 100 |
|
| — |
|
| — |
|
Return of non-vested shares |
| — |
|
| — |
| (500,000 | ) |
| (500 | ) |
| 500 |
|
| — |
|
| — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009 Net Loss |
| — |
|
| — |
| — |
|
| — |
|
| — |
|
| (2,292,444 | ) |
| (2,292,444 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2009 |
| 79,294 |
| $ | 79 |
| 69,742,272 |
| $ | 69,742 |
| $ | 7,530,722 |
| $ | (9,370,224 | ) | $ | (1,769,681 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of shares |
| — |
|
| — |
| 312,500 |
|
| 313 |
|
| 49,688 |
|
| — |
|
| 50,000 |
|
Series E |
| 191,141 |
|
| 191 |
|
|
|
|
|
|
| 1,883,114 |
|
|
|
|
| 1,883,305 |
|
Exercise of warrants |
| — |
|
| — |
| 4,000,000 |
|
| 4,000 |
|
| (4,000 | ) |
| — |
|
| — |
|
Consulting services: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| — |
|
Funding |
| — |
|
| — |
| 1,000,000 |
|
| 1,000 |
|
| 119,000 |
|
| — |
|
| 120,000 |
|
Marketing |
| — |
|
| — |
| 500,000 |
|
| 500 |
|
| 59,500 |
|
| — |
|
| 60,000 |
|
Investor Relations |
| — |
|
| — |
| 100,000 |
|
| 100 |
|
| 22,300 |
|
| — |
|
| 22,400 |
|
Operations |
| — |
|
| — |
| 1,000,000 |
|
| 1,000 |
|
| 79,000 |
|
| — |
|
| 80,000 |
|
Funding |
| — |
|
| — |
| 45,662 |
|
| 46 |
|
| 3,972 |
|
| — |
|
| 4,018 |
|
Funding |
| — |
|
| — |
| 125,000 |
|
| 125 |
|
| 9,875 |
|
| — |
|
| 10,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issued with debt |
| — |
|
| — |
| — |
|
| — |
|
| 57,342 |
|
| — |
|
| 57,342 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010 Net Loss |
| — |
|
| — |
| — |
|
| — |
|
| — |
|
| (3,388,189 | ) |
| (3,388,189 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2010 |
| 270,435 |
| $ | 270 |
| 76,825,434 |
| $ | 76,825 |
| $ | 9,810,513 |
| $ | (12,758,413 | ) | $ | (2,870,805 |
|
See accompanying notes to consolidated financial statements.
F-6
XENACARE HOLDINGS, INC.
STATEMENTS OF CASH FLOWS
|
| Year Ended December 31, |
| ||||
|
| 2010 |
| 2009 |
| ||
|
|
|
|
|
|
|
|
Cash Flows from Operating Activities: |
|
|
|
|
|
|
|
Net loss |
| $ | (3,388,189 | ) | $ | (2,292,444 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
Depreciation and amortization |
|
| 2,500 |
|
| 1,482 |
|
Bad debt expense |
|
| 34,807 |
|
| — |
|
Stock issued for services |
|
| 216,418 |
|
| 297,925 |
|
Impairments and writedowns |
|
| 637,236 |
|
|
|
|
Warrants issued |
|
| 22,148 |
|
| — |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
Accounts receivable |
|
| (132,057 | ) |
| 301,025 |
|
Inventory |
|
| (505,614 | ) |
| (518,215 | ) |
Prepaid expenses and other current assets |
|
| (132,150 | ) |
| 300,453 |
|
Accounts payable and accrued expenses |
|
| 469,289 |
|
| 868,975 |
|
|
|
|
|
|
|
|
|
Net cash used in operating activities |
|
| (2,775,613 | ) |
| (1,040,798 | ) |
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities: |
|
|
|
|
|
|
|
Security deposits |
|
| (6,472 | ) |
|
|
|
Claims receivable |
|
| (29,000 | ) |
| — |
|
Purchase of fixed assets |
|
| (15,000 | ) |
| — |
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
| (50,472 | ) |
| — |
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities: |
|
|
|
|
|
|
|
Proceeds from notes payable |
|
| 2,748,869 |
|
| — |
|
(Repayments on) proceeds from notes payable |
|
| (187,288 | ) |
| 886,395 |
|
Advances from (Payments to) related parties |
|
| — |
|
| (120,940 | ) |
Proceeds from sale of stock |
|
| 50,000 |
|
| 500,000 |
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
| 2,611,581 |
|
| 1,265,455 |
|
|
|
|
|
|
|
|
|
(Decrease) Increase in Cash |
|
| (214,504 | ) |
| 224,657 |
|
Cash, Beginning of Period |
|
| 225,019 |
|
| 362 |
|
|
|
|
|
|
|
|
|
Cash, End of Period |
| $ | 10,515 |
| $ | 225,019 |
|
|
|
|
|
|
|
|
|
Supplemental Information: |
|
|
|
|
|
|
|
Cash paid for interest |
| $ | — |
| $ | — |
|
Cash paid for taxes |
| $ | — |
| $ | — |
|
NonCash Transactions: |
|
|
|
|
|
|
|
Capitalization of debt and other accrued expenses |
| $ | 1,883,305 |
| $ | 604,688 |
|
Conversion of preferred shares |
| $ | — |
| $ | 503 |
|
Cancelled shares |
| $ | — |
| $ | 533 |
|
Shares issued to prepay consulting services |
| $ | — |
| $ | 170,008 |
|
See accompanying notes to consolidated financial statements.
F-7
XENACARE HOLDINGS, INC.
NOTES TO FINANCIAL STATEMENTS
NOTE 1. – ORGANIZATION AND NATURE OF BUSINESS
Organization and Nature of Business
XenaCare Holdings, Inc. (the “Company”, “XenaCare”, “XC Holdings”, “we”, “us” or “our”) was organized under the laws of Florida in June 2005 to formulate, market and distribute a line of clinical and protective nutrition supplement products (“NSPs”) as well as homeopathic medication, detoxification and pet care products.
Our Clinical NSP products group includes our proprietary formulations - XenaCor, XenaTri and XenaZyme Plus, which will be sold through mass media buys (radio and television advertising), web sales and other channels of distribution.
On September 29, 2010, XenaCare Holdings entered into a Private Labeling Agreement with Renaissance Health Publishing, LLC (“Renaissance”) of Boca Raton, Florida to market our clinical products. These products address major issues concerning prevention of heart disease. XenaCare will provide the finished products to Renaissance who is currently developing the labels, the marketing materials and strategies for these retail products. Because the Renaissance model is to educate the consumer through direct response sales, these unique supplements will necessarily receive greater personal attention by the consumer.
Our Protective NSP product group is directed to the energy/lifestyle performance market. Our initial product, SunPill™, is formulated to protect the skin when exposed to damaging ultraviolet rays. During the third quarter of 2010, we had the product reevaluated and as a result were able to extend its shelf life for an additional two years. We are currently in negotiations with a distributor in Cypress to assume the entire line for distribution in the European market. Although we believe that we will ultimately recover our product costs, because of certain delays in consummating the Cypress sale, we have fully impaired the inventory in fourth quarter of 2010.
Our Homeopathic Medication product line is lead by Cobroxin. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Available in a topical gel that relieves pain associated with joints, repetitive stress and arthritis, and in an oral spray that is formulated to relieve lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, Cobroxin™ is derived from cobra venom.
Our Detoxification product line is led by Zeolite. We exclusively market and distribute Zeolite from Mineral Sciences, LLC within the United States. Zeolite is a cellular cleanse and detoxification product designed as an effective solution for removing heavy metals and toxins from the body. Research has also shown that the product’s ingredients may help reduce viral replication and support healthy blood sugar levels. Additionally, this product improves nutrient absorption, supports immune system function and reduces symptoms of allergies.
Our new Pet Care product line is led by EstraPet™. On September 8, 2010, XenaCare Holdings entered into an exclusive agreement with Dr. Phillip Schoenwetter whereby XenaCare gained all rights to the trademark EstraPet™; to the domain www.estrapet.com and to the United States Patent Pending under the caption "Treatment for Domestic Animals Having Sex Hormone Deficiencies using Soy Germ Isoflavones". EstraPet™ answers the need for treating the unintended consequences caused by spaying and neutering and is the only known natural hormone modulator available on the market today.
History of the Company
While the Company was organized in 2005, its predecessor, XenaCare LLC was organized in 2001. Thereafter, the Company entered into an exchange agreement with certain members of XenaCare LLC and such members exchanged their interest in XenaCare LLC for an aggregate of 800,000 shares of XenaCare Holdings, Inc. common stock, which represented a value of $1,600,000.
On January 5, 2009, XenaCare amended its Articles of Incorporation to increase the number of authorized shares of common stock from 45 million to 200 million.
F-8
NOTE 1. – ORGANIZATION AND NATURE OF BUSINESS (Continued)
In May, 2009, NutraPharma, Inc. awarded to XenaCare the US marketing rights to Cobroxin. NutraPharma is a biotechnology company that is developing treatments for adrenomyeloneuropathy, HIV and multiple sclerosis. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. The Company has sales agreements with many major retailers.
In May, 2009, Mineral Sciences, Inc. awarded XenaCare the exclusive license to market and distribute a cellular cleanse and detoxification product called Zeolite for retail distribution designed as an effective solution for removing heavy metals and toxins from the body.
In December, 2009, all of the Company’s subsidiaries were merged into XenaCare Holdings, Inc.
NOTE 2. – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Terms and Definitions
| Company |
| “XenaCare”, “XC Holdings”, “we”, “us” or “our” |
| ASC |
| Accounting Standards Codification |
| ASU |
| Accounting Standards Update |
| FASB |
| Financial Accounting Standards Board |
| FIFO |
| First-in, First-out |
| GAAP (US) |
| Generally Accepted Accounting Principals |
| NSP |
| Nutrition Supplement Product |
| SEC |
| Securities Exchange Commission |
| SFAS or |
|
|
| FAS |
| Statement of Financial Accounting Standards |
| Q409-QTR |
| Three months Ended December 31, 2009 |
| 2009-YTD |
| Twelve months Ended December 31, 2009 |
| Q410-QTR |
| Three months Ended December 31, 2010 |
| 2010-YTD |
| Twelve months Ended December 31, 2010 |
Basis of Accounting
The financial statements are prepared using the accrual basis of accounting where revenues and expenses are recognized in the period in which they were incurred. The basis of accounting conforms to accounting principles generally accepted in the United States of America.
Principles of Consolidation and Presentation
In 2010, the financial statements include the accounts of the Company since in December 2009; the Company merged all of its subsidiaries into the Company (XenaCare Holdings, Inc.).
In 2009, the financial statements were consolidated and include the accounts of the Company (XenaCare Holdings, Inc.) and its wholly-owned subsidiaries: BRS, Inc.; XenaCare, LLC; XenaStaff, LLC; and XenaCeutical, LLC and Raw Material Ingredients, Inc. All material intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions it may undertake in the future, they may ultimately differ from actual results.
F-9
NOTE 2. – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Risks and Uncertainties
The Company’s business could be impacted by continuing price pressure on its product manufacturing, acceptance of its products in the marketplace, new competitors, changes in federal and/or state legislation and other factors. Adverse changes in these areas could negatively impact the Company’s financial position, results of operations and cash flows.
Going Concern
The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has reported a net loss from operations of $3,388,189 for the year ended December 31, 2010, accumulated deficit of $12,758,413 and a working capital deficit of $2,918,777 as of December 31, 2010. As shown in the accompanying financial statements, the Company’s operating and capital requirements in connection with operations have been and will continue to be significant.
The recurring losses from operations and increased contractual agreements raise doubt about the Company’s ability to continue as a going concern. Based on current plans, the Company anticipates that revenues earned from Cobroxin™ and Zeolite product sales will be the primary source of funds for operating activities. In addition to existing cash, the Company may rely on bank borrowing, if available, or sales of securities to meet the basic capital and liquidity needs for the next 12 months. Additional capital may be sought to fund the expansion of product lines and marketing efforts, which may also include bank borrowing, or a private placement of securities. Our ability to continue as a going concern is dependent upon our ability to generate sales from our new products and our obtaining adequate capital to fund losses until we become profitable. There can be no assurance that management’s plans will be successful.
The financial statements have been prepared on a “going concern” basis and accordingly do not include any adjustments that might result from the outcome of this uncertainty.
Cash
Cash equivalents include all highly liquid debt instruments with original maturities of three months or less which are not securing any corporate obligations.
Accounts Receivable
Accounts receivable are reported at net realizable value. The Company establishes an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written-off when it is determined that the amounts are uncollectible. At December 31, 2010 and 2009, the allowance for doubtful accounts was $315,686 and $48,697, respectively.
Inventory
Inventory is reported at the lower end of cost or market on the first-in, first-out (FIFO) method. Our inventory is subject to expiration and accordingly quantities purchased and sell through rates are periodically monitored for potential overstocking or pending expiration as a basis for establishing the appropriate reserve for any estimated expiration or obsolescence. The Company’s principal brands are XenaCor, XenaTri, XenaZyme and its newest product lines, Cobroxin™, Zeolite™ and EstraPet™.
At December 31, 2010 and 2009, the allowance for obsolete or expired inventory was $34,386 and $55,544, respectively. In addition, during the fourth quarter of 2010, the Company impaired the carrying value of the remaining SunPill inventory totaling $381,126 due to delays in consummating a sale.
F-10
NOTE 2. – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Office Furniture and Equipment
Office furniture and equipment are recorded at cost and depreciation is provided using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance of equipment are charged to expense as incurred. Major replacements and betterments are capitalized and depreciated over the remaining useful lives of the assets.
Office furniture and equipment is depreciated over various lives ranging from 5 to 10 years. Depreciation expense for the year ended December 31, 2010 and 2009 was $2,500 and $1,482, respectively.
Revenue Recognition
The Company’s product revenues represent primarily sales of SunPill™, XenaCor, XenaTri, XenaZyme and Cobroxin™. Revenue is recognized when a product is shipped. The Company outsources its fulfillment (delivery) process to a third party for most of its products.
The Company’s revenue recognition policies are in compliance with ASC Topic 605, Revenue Recognition, which establishes criteria that must be satisfied before revenue is realized or realizable and earned. The Company recognizes revenue when all of the following four criteria are met:
·
persuasive evidence of a sales arrangement exists,
·
delivery has occurred,
·
the sales price is fixed or determinable, and
·
collectability is probable.
Shipping and handling charges related to sales transactions are recorded as sales revenues when billed to customers or included in the sales price in accordance with ASC Topic 605, shipping and handling costs are included in cost of revenue.
The Company accepts product returns and will issue a credit, refund or product exchange. To date, product returns have occurred but are not considered material.
The costs that the Company incurs for “cooperative” advertising programs, end cap placement, shelf placement costs, slotting fees and marketing development funds, if any, are are netted against revenues on the Company’s Statements of Operations.
Research and Development
The Company does not engage in research and development as defined in ASC Topic 730 Research and Development Costs. However, the Company does incur formulation costs that include salaries, materials and consultant fees. These costs are classified as selling, general and administrative expenses in the consolidated statements of operations.
Income Taxes
We recognize deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that are expected to be recovered. We provide a valuation allowance for deferred tax assets for which we do not consider realization of such assets to be more likely than not.
Earnings per share
The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.
For the years ended December 31, 2010 and 2009, diluted net loss per share does not include potential common shares derived from convertible notes payable, stock options and warrants because as a result of the Company incurring losses, their effect would have been anti-dilutive.
F-11
NOTE 2. – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Segment Information
ASC Topic 280, Disclosures about Segments of an Enterprise and Related Information, established standards for the way that public business enterprises report information about operating segments in annual financial statements and requires those enterprises to report selected information about operating segments in interim financial reports issued to stockholders. The Company operates in one segment for management reporting purposes.
Fair Value of Financial Instruments
In January 2008, we adopted the provisions under FASB for Fair Value Measurements, which define fair value for accounting purposes, establishes a framework for measuring fair value and expands disclosure requirements regarding fair value measurements. Our adoption of these provisions did not have a material impact on our consolidated financial statements. Fair value is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. We currently do not have any financial assets and liabilities that are recurring that would require us to disclosure them at fair value.
Reclassification
Certain reclassifications have been made to conform to prior periods’ data to the current presentation. These reclassifications had no effect on reported losses.
NOTE 3. – RECENT ACCOUNTING PRONOUNCEMENTS
Recent accounting pronouncements that the Company has adopted or that will be required to adopt in the future are summarized below.
Income Taxes: In September 2009, the FASB issued ASU 2009-06, Income Taxes (Topic 740), ”Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities”, which provides implementation guidance on accounting for uncertainty in income taxes, as well as eliminates certain disclosure requirements for nonpublic entities. For entities that are currently applying the standards for accounting for uncertainty in income taxes, this update shall be effective for interim and annual periods ending after September 15, 2009. For those entities that have deferred the application of accounting for uncertainty in income taxes in accordance with paragraph 740-10-65-1(e), this update shall be effective upon adoption of those standards. The adoption of this standard did not have an impact on the Company’s consolidated financial position and results of operations since this accounting standard update provides only implementation and disclosure amendments.
Fair Value Measurements: In September 2009, the FASB has published ASU 2009-12, “Fair Value Measurements and Disclosures (Topic 820) - Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent)”. This ASU amends Subtopic 820-10, “Fair Value Measurements and Disclosures – Overall”, to permit a reporting entity to measure the fair value of certain investments on the basis of the net asset value per share of the investment (or its equivalent). This ASU also requires new disclosures, by major category of investments including the attributes of investments within the scope of this amendment to the Codification. The guidance in this Update is effective for interim and annual periods ending after December 15, 2009. Early application is permitted. The adoption of this standard did not have any impact on the Company’s consolidated financial position and results of operations.
F-12
NOTE 3. – RECENT ACCOUNTING PRONOUNCEMENTS (Continued)
Transfers of Financial Assets: In December 2009, the FASB has published ASU 2009-16 “Transfers and Servicing (Topic 860): Accounting for Transfers of Financial Assets.” ASU 2009-16 is a revision to ASC 860, “Transfers and Servicing,” and amends the guidance on accounting for transfers of financial assets, including securitization transactions, where entities have continued exposure to risks related to transferred financial assets. ASU 2009-16 also expands the disclosure requirements for such transactions. This ASU will become effective for us on April 1, 2010. The adoption of this standard did not have any impact on the Company’s consolidated financial position and results of operations.
Consolidations: In December 2009, the FASB has published ASU 2009-17 “Consolidations (Topic 810): Improvements to Financial Reporting by Enterprises Involved with Variable Interest Entities.” ASU 2009-17 amends the guidance for consolidation of VIEs primarily related to the determination of the primary beneficiary of the VIE. The adoption of this standard did not have any impact on the Company’s consolidated financial position and results of operations.
Equity: In January 2010, the FASB has published ASU 2010-01 “Equity (Topic 505) - Accounting for Distributions to Shareholders with Components of Stock and Cash—a consensus of the FASB Emerging Issues Task Force,” as codified in ASC 505. ASU No. 2010-01 clarifies the treatment of certain distributions to shareholders that have both stock and cash components. The stock portion of such distributions is considered a share issuance that is reflected in earnings per share prospectively and is not a stock dividend. The amendments in this Update are effective for interim and annual periods ending on or after December 15, 2009, and should be applied on a retrospective basis. Early adoption is permitted. The adoption of this standard did not have an impact on the Company’s (consolidated) financial position and results of operations.
Consolidation: In January 2010, the FASB has published ASU 2010-02 “Consolidation (Topic 810) - Accounting and Reporting for Decreases in Ownership of a Subsidiary—a Scope Clarification,” as codified in ASC 810, “Consolidation.” ASU No. 2010-02 applies retrospectively to April 1, 2009, our adoption date for ASC 810-10-65-1 as previously discussed in this financial note. This ASU clarifies the applicable scope of ASC 810 for a decrease in ownership in a subsidiary or an exchange of a group of assets that is a business or nonprofit activity. The ASU also requires expanded disclosures. The amendments in this Update are effective for interim and annual periods ending on or after December 15, 2009, and should be applied on a retrospective basis. The adoption of this standard did not have any impact on the Company’s consolidated financial position and results of operations.
Fair Value Measurements: In January 2010, the FASB has published ASU 2010-06 “Fair Value Measurements and Disclosures (Topic 820): - Improving Disclosures about Fair Value Measurements. ASU No. 2010-06 clarifies improve disclosure requirement related to fair value measurements and disclosures – Overall Subtopic (Subtopic 820-10) of the FASB Accounting Standards Codification. The new disclosures and clarifications of existing disclosures are effective for interim and annual reporting periods beginning after December 15, 2009, except for the disclosure about purchase, sales, issuances, and settlement in the roll forward of activity in Level 3 fair value measurements. Those disclosures are effective for fiscal years beginning after December 15, 2010, and for interim periods within those fiscal years. The amendments in this Update are effective for interim and annual periods ending on or after December 15, 2009, and should be applied on a retrospective basis. The adoption of this standard did not have a material impact on the Company’s consolidated financial position and results of operations.
Income Taxes: In April 2010, the FASB issued ASU 2010-12. “Income Taxes” (Topic 740). ASU 2010-12 amends FASB Accounting Standard Codification subtopic 740-10 Income Taxes to include paragraph 740-10-S99-4. On March 30, 2010 The President signed the Health Care & Education Affordable Care Act reconciliation bill that amends its previous Act signed on March 23, 2010. FASB Codification topic 740, Income Taxes, requires the measurement of current and deferred tax liabilities and assets to be based on provisions of enacted tax law. The effects of future changes in tax laws are not anticipated.” Therefore, the different enactment dates of the Act and reconciliation measure may affect registrants with a period-end that falls between March 23, 2010 (enactment date of the Act), and March 30, 2010 (enactment date of the reconciliation measure). However, the announcement states that the SEC would not object if such registrants were to account for the enactment of both the Act and the reconciliation measure in a period ending on or after March 23, 2010, but notes that the SEC staff “does not believe that it would be appropriate for registrants to analogize to this view in any other fact patterns.” The adoption of this standard did not have a material impact on the Company’s consolidated financial position and results of operations.
F-13
NOTE 3. – RECENT ACCOUNTING PRONOUNCEMENTS (Continued)
Stock Compensation: In April 2010, the FASB issued ASU 2010-13 “Stock Compensation” (Topic 718). ASU 2010-13 provides amendments to Topic 718 to clarify that an employee share-based payment award with an exercise price denominated in the currency of a market in which a substantial portion of the entity's equity securities trades should not be considered to contain a condition that is not a market, performance, or service condition. Therefore, an entity would not classify such an award as a liability if it otherwise qualifies as equity. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2010. The amendments in this Update should be applied by recording a cumulative-effect adjustment to the opening balance of retained earnings. The cumulative-effect adjustment should be calculated for all awards outstanding as of the beginning of the fiscal year in which the amendments are initially applied, as if the amendments had been applied consistently since the inception of the award. The cumulative-effect adjustment should be presented separately. Earlier application is permitted. The adoption of this standard did not have any impact on the Company’s consolidated financial position and results of operations.
Allowance for Credit Losses: In July 2010, the FASB issued ASU No. 2010-20 “Receivables” (Topic 310). ASU No. 2010-20 provides financial statement users with greater transparency about an entity’s allowance for credit losses and the credit quality of its financing receivables. This update is intended to provide additional information to assist financial statement users in assessing an entity’s credit risk exposures and evaluating the adequacy of its allowance for credit losses. The amendments in this update apply to both public and nonpublic entities with financing receivables, excluding short-term trade accounts receivable or receivables measured at fair value or lower of cost or fair value. The objective of the amendments in ASU No. 2010-20 is for an entity to provide disclosures that facilitate financial statement users’ evaluation of (1) the nature of credit risk inherent in the entity’s portfolio of financing receivables, (2) How that risk is analyzed and assessed in arriving at the allowance for credit losses and (3) The changes and reasons for those changes in the allowance for credit losses. The entity must provide disclosures about its financing receivables on a disaggregated basis. For public entities ASU No. 2010-20 is effective for interim and annual reporting periods ending on or after December 15, 2010. For nonpublic entities ASU No. 2010-20 will become effective for annual reporting periods ending on or after December 15, 2011. Adoption of ASU No. 2010-20 did not have a material impact on the consolidated financial statements.
Technical Amendments: In August 2010, the FASB issued ASU No. 2010-21 “Accounting for Technical Amendments to Various SEC Rules and Schedules” and ASU No. 2010-22 “Accounting for Various Topics – Technical Corrections to SEC Paragraphs”. ASU No 2010-21 amends various SEC paragraphs pursuant to the issuance of Release no. 33-9026: Technical Amendments to Rules, Forms, Schedules and Codification of Financial Reporting Policies. ASU No. 2010-22 amends various SEC paragraphs based on external comments received and the issuance of SAB 112, which amends or rescinds portions of certain SAB topics. Both ASU No. 2010-21 and ASU No. 2010-22 are effective upon issuance. The amendments in ASU No. 2010-21 and No. 2010-22 did not have a material impact on the Company’s financial statements.
Other Expenses: In December 2010, the FASB issued ASU No. 2010-27 “Other Expenses (Topic 720).” ASU No. 2010-27 addresses questions concerning how pharmaceutical manufacturers should recognize and classify in their income statements fees mandated by the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act (the “Acts”). The amendments in this update specify that the liability for the fee should be estimated and recorded in full upon the first qualifying sale with a corresponding deferred cost that is amortized to expense using a straight-line method of allocation unless another method better allocates the fee over the calendar year that is payable. The amendments in this update are effective for calendar years beginning after December 31, 2010, when the fee initially becomes effective. The Company is evaluating the impact ASU No. 2010-27 will have on the consolidated financial statements.
F-14
NOTE 3. – RECENT ACCOUNTING PRONOUNCEMENTS (Continued)
Intangibles – Goodwill and Other: In December 2010, the FASB issued ASU No. 2010-28 “Intangibles – Goodwill and Other (Topic 350).” ASU No. 2010-28 addresses questions about entities with reporting units with zero or negative carrying amounts because some entities concluded that Step 1 of the goodwill impairment test, as stated in Topic 350, is passed in those circumstances because the fair value of their reporting unit will generally be greater than zero. The amendments in this update do not provide guidance on how to determine the carrying amount or measure the fair value of the reporting unit. The amendments in this update modify Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. For public entities, the amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2010. Early adoption is permitted. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Nonpublic entities may early adopt the amendments using effective date for public entities. The Company is evaluating the impact ASU No. 2010-28 will have on the consolidated financial statements.
Business Combinations: In December 2010, the FASB issued ASU No. 2010-29 “Business Combinations (Topic 805).” ASU No. 2010-29 addresses the diversity in practice about the interpretation of the pro forma revenue and earnings disclosure requirements for business combinations. The amendments in this update specify that if a public entity presents comparative financial statements, the entity should disclose revenue and earnings of the combined entity as though the business combination(s) that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. The amendments in this update also expand the supplemental pro forma disclosures under Topic 805 to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings. The amendments in this update are effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2010. Early adoption is permitted. The Company is evaluating the impact ASU No. 2010-29 will have on the consolidated financial statements.
A variety of proposed or otherwise potential accounting standards are currently under study by standard-setting organizations and various regulatory agencies. Because of the tentative and preliminary nature of these proposed standards, management has not determined whether implementation of such proposed standards would be material to the Company’s consolidated financial statements.
Other ASUs not effective until after December 31, 2010, are not expected to have a significant effect on the Company’s consolidated financial position or results of operations.
NOTE 4. – ACCOUNTS RECEIVABLE
Significant components of accounts receivable at December 31, 2010 and December 31, 2009 consist of:
|
| 2010 |
| 2009 |
| ||
|
|
|
|
|
|
|
|
Receivables non-factored |
| $ | 202,154 |
| $ | 78,698 |
|
Receivables factored |
|
| 240,786 |
|
| — |
|
|
|
| 442,940 |
|
| 78,698 |
|
Allowances |
|
| (315,686 | ) |
| (48,696 | ) |
|
|
|
|
|
|
|
|
|
| $ | 127,254 |
| $ | 30,002 |
|
F-15
NOTE 5. – INVENTORY
Significant components of inventory at December 31, 2010 and December 31, 2009 consist of:
|
| 2010 |
| 2009 |
| ||
|
|
|
|
|
|
|
|
Bulk product |
| $ | 34,386 |
| $ | 96,000 |
|
Merchandise inventory |
|
| 970,696 |
|
| 788,862 |
|
|
|
| 1,005,082 |
|
| 884,862 |
|
Allowances for expiration |
|
| (34,386 | ) |
| (55,544 | ) |
|
|
|
|
|
|
|
|
|
| $ | 970,696 |
| $ | 829,318 |
|
Bulk product – Bulk product consists of completed unpackaged loose SunPill® product that has been stored in barrels awaiting commercial packaging to make it market ready for distribution. As discussed below, the Company has arranged for the disposition of its existing SunPill® inventory and since it no longer considers the SunPill® inventory market ready for distribution, package SunPill® has been reclassified as bulk product. During 2010 the Company has been attempting the liquidation of this merchandize along with any bulk product, however as a result of delays in consummating a final sale, consequently the Company has fully impaired the SunPill® inventory totaling $381,126, even though the SunPill® inventory has been retested and the shelf life has been extended for two years.
Merchandise inventory - Merchandise inventory consists primarily of the Cobroxin® product along with lesser quantities of XenaCore. Our formulations are batch controlled and carry an expiration date in accordance with applicable government regulations. Any product approaching their expiration date have been destroyed and removed from the inventory. The Company establishes an allowance on the remaining inventory, based on the estimated sell through rate for each product, before their expiration.
NOTE 6. – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Significant components of accounts payable and accrued expenses at December 31, 2010 and 2009 consist of:
|
| 2010 |
| 2009 |
| ||
|
|
|
|
|
|
|
|
Trade payables |
| $ | 256,786 |
| $ | 447,785 |
|
Accrued professional fees |
|
| — |
|
| 28,500 |
|
Accrued payroll |
|
| 370,000 |
|
| 433,333 |
|
Accrued interest |
|
| 272,188 |
|
| 158,104 |
|
Other accrued expenses |
|
| 155,288 |
|
| 54,167 |
|
|
|
|
|
|
|
|
|
|
| $ | 1,054,262 |
| $ | 1,121,889 |
|
NOTE 7. – REVOLVING CREDIT FACILITY
On September 1, 2010, the Company entered into a financing agreement with FT Trade Financial Corp (“FT Trade”) for a maximum borrowing of up to $600,000. The arrangement was based on a recourse factoring of the Company’s accounts receivables. Certain accounts receivable of the Company were pledged as collateral for the FT Trade facility. Under the arrangement, FT Trade typically advanced to the Company 85% of the total amount of accounts receivable factored. FT Trade retained 15% of the outstanding factored accounts receivable as a reserve, until the customer paid the factored invoice to FT Trade. As of December 31, 2010 the liability outstanding on the revolving credit facility is $259,174.
F-16
NOTE 8. – NOTES PAYABLE - CURRENT
Significant components of notes payable – current at December 31, 2010 and 2009 consist of:
|
| 2010 |
| 2009 |
| ||
|
|
|
|
|
|
|
|
Related parties |
| $ | 226,092 |
| $ | 500,138 |
|
Shareholder loans |
|
| 1,850,000 |
|
| 700,000 |
|
Sun Packing, Inc. |
|
| 977,000 |
|
| 977,000 |
|
Other advances |
|
| 75,000 |
|
| — |
|
Financial institutions |
|
| 5,066 |
|
| — |
|
Debt discount |
|
| (57,342 | ) |
| — |
|
Less: Amortization |
|
| 22,148 |
|
| — |
|
|
|
|
|
|
|
|
|
|
| $ | 3,097,964 |
| $ | 2,177,138 |
|
Related Parties - Notes payable to related parties were issued in various traunches, each mature one year from issuance and bear interest at 15%. The lenders are related parties to the Company through common executive management as our CFO and President are also officers in the lenders. The notes matured on June 30, 2009 however, during the first quarter of 2010, the parties agreed to convert $346,387 of these notes into 34,639 shares of Series E preferred stock. In addition, during the third and fourth quarters of 2010, the Company borrowed approximately $58,000 and $29,342, respectively which provided supplemental working capital.
Shareholder Loans – Unsecured notes payable to a shareholder were issued in various traunches commencing in January 2009, each mature one year from issuance and bear interest at from 12%-15%. During the first quarter of 2010, the shareholder advanced an additional $1,500,000 and then converted $1,000,000 of outstanding debt into 100,000 shares of Series E preferred shares. During the third quarter of 2010, the shareholder advanced an additional $50,000, the proceeds of which were used to acquire product and promote its brand.
During the third quarter of 2010, the Company borrowed $130,288 from another shareholder, the proceeds of which were used to acquire inventory. Interest accrues at 15% and the note matures in August 2011 however the note was repaid in the fourth quarter of 2010.
Sun Packing, Inc. - The Sun Packing, Inc. note originated during merger negotiations with the Company during the third and fourth quarters of 2008. It is the company's position that Sun Packing did not conclude the merger and the notes may not be paid. The note is personally guaranteed by our officers and bears interest at 6%. The note is payable upon demand. To date the note has not been called.
Other Advances – During the fourth quarter in 2010, the Company received $75,000 in advances to secure inventory from Jega Corp and a vendor. The advances were informal and are expected to be repaid from collections in first quarter of 2011. The advances are not collateralized and do not accrue interest.
NOTE 9. – COMMITMENTS AND CONTINGENCIES
The Company, during the year operated under several material agreements as listed below:
Consulting service / employment agreements
·
Employment agreements - Employment agreements with two individuals for their services in the areas of sales (our President), operations and mergers and acquisitions (our CFO) were terminated on December 31, 2009 by mutual consent. All accrued and unpaid compensation and benefits totaling $562,500 were converted into 56,250 Series E preferred shares. New verbal employment agreements were entered into with these individuals, which provide for monthly draws of $5,000 and quarterly bonus based on performance. The agreements can be terminated at any time.
·
Beauty Development - In December 2009, we entered into a three year agreement with Beauty Development Corporation, to provide distribution management, development and product merchandising services. The Company issued 8,475 shares of Series E preferred shares which calls for performance based vesting over the three year term. This agreement has been fully prepaid.
F-17
Marketing agreements
·
Creative Management and Arnot – During the third quarter of 2010, the Company entered into a new image marketing and branding agreement with Creative Management, Inc. and a companion spokesperson agreement with Dr. Bob Arnot, a nationally known medical and news correspondent. The terms of the agreements provide for image marketing and branding services for 36 months. The contract was prepaid through the issuance of 1 million common shares valued at $.12 each, the fair value of the shares at the execution of the agreement. Accordingly, $120,000 has been recorded as a prepaid expense and will be amortized over the next 36 months.
·
Nutritional Alliances, Inc - In December 2009, we also entered into a three year agreement with Nutritional Alliances, Inc to provide market penetration and expand our customer base. The Company issued 8,475 shares of Series E preferred shares which calls for performance based vesting over the three year term. This agreement has been fully prepaid.
Lease for office facilities
·
Boca Raton office – In March 2010, the Company entered into a 3 year lease agreement for its new corporate headquarters in Boca Raton, Florida. The Company occupied the new facility in June 2010. The lease provides for the first four months of rent waived.
Distribution agreement
·
Nutra-Pharma – In March 2010, the Company entered into a 5 year exclusive US marketing and distribution agreement with the manufacturer of Cobroxin. The agreement requires that the Company make minimum product purchases of $250,000 per quarter.
Summary of commitments
|
| 2011 |
| 2012 |
| 2013 |
| Beyond |
| Total |
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employment agreements |
| $ | — |
| $ | — |
| $ | — |
| $ | — |
| $ | — |
|
Beauty Development Corporation |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
Creative Management and Arnot |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
Nutritional Alliances, Inc |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
Boca Raton office lease (current) |
|
| 35,189 |
|
| 38,513 |
|
| 16,610 |
|
| — |
|
| 90,312 |
|
Nutra Pharma |
|
| 1,000,000 |
|
| 1,000,000 |
|
| 1,000,000 |
|
| 2,000,000 |
|
| 5,000,000 |
|
|
| $ | 1,035,189 |
| $ | 1,038,513 |
| $ | 1,016,610 |
| $ | 2,000,000 |
| $ | 5,090,312 |
|
NOTE 10. - ADVERTISING
Advertising within SG&A includes print and other advertising production costs which are expensed the first time the advertising takes place. The costs of promotional displays are expensed in the period in which they are shipped to customers. Advertising expenses were $1.8 million and $.7 million for 2010 and 2009, respectively, and were included in SG&A in the Company’s Consolidated Statements of Operations. The Company also has various arrangements with customers pursuant to its trade terms to reimburse them for a portion of their advertising costs, which provide advertising benefits to the Company. Additionally, from time to time the Company may pay fees to customers in order to expand or maintain shelf space for its products. The costs that the Company incurs for “cooperative” advertising programs, end cap placement, shelf placement costs, slotting fees and marketing development funds, if any, are are netted against revenues on the Company’s Statements of Operations.
NOTE 11. – COMMON AND PREFERRED STOCK
Common Stock
The Articles of Incorporation of the Corporation authorizes the issuance of two hundred million (200,000,000) shares of common stock, par value $0.001 per share.
The Company’s shares commenced quotation on the Over the Counter Bulletin Board on March 5, 2008. The Company’s quotation symbol is XCHO:OTC.
F-18
NOTE 11. – COMMON AND PREFERRED STOCK (Continued)
During the first quarter of 2009, the Company issued 10,748,340 shares to convert 500,000 Preferred A shares.
Also during the first quarter of 2009, the Company had a net retirement of 33,333 shares in several exchange transactions, in which 100,000 shares were retired in exchange for 66,667 shares issued.
During the second quarter of 2009, the Company retired 500,000 non vested shares which were returned to the Company.
In September 2009, we sold 12,500,000 shares of common stock to an accredited investor for $500,000.
During the fourth quarter of 2009, we issued 3,000,750 shares of common stock to retire 2,623 shares of Series F preferred stock. The 2,632 shares of Series F preferred stock was issued in 2009 in exchange for professional services in connection with the Sun Packing transaction. The shares were recorded at their fair value of $263,150.
Also during the fourth quarter of 2009, we issued 1,000,000 shares of common stock in exchange for services from various consultants. The shares were recorded at their fair value of $16,000.
During the first quarter of 2010, 4,000,000 of outstanding warrants were exercised and exchanged for common shares. The warrants were originally granted in connection with a private stock sale in Q3 2009.
During the third quarter of 2010, we issued 1,600,000 shares of common stock which were recorded at their aggregate fair value totaling $202,400 as follows:
·
1,000,000 shares totaling $120,000 were issued to a consultant who provided funding services, which were subsequently canceled and returned to treasury in Q1 2011
·
500,000 shares totaling $60,000 were issued to a consultant who provided marketing services. The Company has capitalized this cost at December 31, 2010 and will record a charge to marketing expenses as the services are incurred.
·
100,000 shares totaling $22,400 were issued to a consultant who provided investor relations services.
Also during the third quarter of 2010, we also sold 312,500 shares of common stock for $50,000 to an accredited investor.
During the fourth quarter of 2010, we issued 1,170,662 shares of common stock which were recorded at their aggregate fair value totaling $94,018 as follows:
·
1,000,000 shares totaling $80,000 were issued to a consultant who provided operational services regarding the launching of EstraPet products.
·
45,662 shares totaling $4,018 were issued to a consultant who provided funding services, which were subsequently canceled and returned to treasury in Q1 2011.
·
125,000 shares totaling $10,000 were issued to a consultant who provided funding services.
Appropriate expenses or prepaid services for long term agreements have been recorded.
Preferred Stock
The Articles of Incorporation of the Corporation authorizes the issuance of five million (5,000,000) shares of preferred stock, par value $0.001 per share and further authorizes the Board of Directors to divide and establish any or all of the shares of Preferred Stock into one or more series and to fix the designation of each such share, and its preferences, conversion rights, cumulative, relative, participating, optional, or other rights, including voting rights, qualifications, limitations, or restrictions thereof.
During the first quarter of 2009, the Company converted 500,000 shares of Series A Preferred stock to 10,748,340 shares of restricted common stock.
F-19
NOTE 11. – COMMON AND PREFERRED STOCK (Continued)
During December of 2009, the board of directors authorized the issue of up to 500,000 shares of Series E preferred stock. The Series E Preferred Stock has a stated value and liquidation preference of $10.00 per share and is convertible into common shares at a conversion rate of $10.00 divided by the value of the Common Stock when the Preferred Shares are issued. The Series E Preferred shares pay dividends at a rate of fifteen (15%) percent per annum and are paid only in common stock when declared by the Board of Directors. The Series E Preferred shares have voting rights as if converted to common shares.
At any time prior to December 31, 2012, the holder is entitled to subscribe for one share (the “Warrant Shares”) of the common stock, $ .001 par value, for each Common share converted from Series E Preferred Shares. The Warrant Share may be exercised in a cashless transaction identical to the conversion provisions of the Series E Preferred Shares converted into Common Shares, with the price of the Warrant Shares fixed at the same price as the Converted Preferred Shares.
During the fourth quarter of 2009, the company issued 79,294 shares of Series E Preferred stock. 68,000 shares were issued to corporate executives for accrued salaries and stockholder loans and 10,000 shares were issued as a bonus to one employee and one outside consultant.
During the first quarter of 2010, we issued 191,141 shares of Series E Preferred Stock totaling $1,883,305 as follows:
·
56,502 shares totaling $536,918 were issued to satisfy all accrued and unpaid compensation and benefits for two consultants, one who provided acquisition and financing services and one who provided administration services. There services were terminated in 2009 and no new agreements were entered into with these individuals.
·
100,000 shares totaling $1,000,000 were issued to satisfy $1,000,000 of outstanding debt.
·
34,639 shares totaling $346,387 were issued to two employees (the CFO and the President) who are lenders to the Company to satisfy $346,387 of their outstanding debt.
Warrants
During the fourth quarter of 2010, we issued 229,734 of warrants to purchase common stock. The warrants were issued in connection with obtaining financing from certain related parties. The warrants vest immediately and are valid for 5 years. The warrants are cashless, fully paid and non-assessable. The warrants were recorded as debt discount, at their fair value of $57,342 using the Black-Scholes-Merton pricing model. The debt discount will be amortized over the term of the related debt.
|
| Shares |
| Weighted- |
| Weighted- |
| Aggregate |
| ||||
Outstanding at January 1, 2010 |
|
| 12,500,000 |
| $ | 0.01 |
|
| 5.0 |
| $ | 500,000 |
|
Issued |
|
| 229,734 |
| $ | 0.00 |
|
| 5.0 |
|
|
|
|
Exercised |
|
| (4,000,000 | ) | $ | 0.01 |
|
| 5.0 |
|
|
|
|
Forfeited |
|
| — |
| $ | — |
|
|
|
|
|
|
|
Outstanding at December 31, 2010 |
|
| 8,729,734 |
| $ | 0.01 |
|
| 5.0 |
| $ | 351,487 |
|
Exercisable at December 31, 2010 |
|
| 8,729,734 |
| $ | 0.01 |
|
| 5.0 |
| $ | 351,487 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-20
NOTE 12. – INCOME TAXES
The provision (benefit) for income taxes is summarized as follows:
|
| Year Ended December 31, |
| ||||
|
| 2010 |
| 2009 |
| ||
Current: |
|
|
|
|
|
|
|
Federal |
| $ | — |
| $ | — |
|
State |
|
| — |
|
| — |
|
|
|
|
|
|
|
|
|
Deferred: |
|
|
|
|
|
|
|
Federal |
|
| 1,185,866 |
|
| 802,355 |
|
State |
|
| 152,469 |
|
| 103,160 |
|
|
|
|
|
|
|
|
|
Increase in Valuation allowance |
|
| (1,338,335 | ) |
| (905,515 | ) |
|
|
|
|
|
|
|
|
Total provision (benefit) for income taxes |
| $ | — |
| $ | — |
|
The provision for income taxes differs from the amount computed by applying the federal statutory rate to income (loss) before provision (benefit) for income taxes as follows:
|
| Year Ended December 31, |
| ||||
|
| 2010 |
| 2009 |
| ||
Expected provision(benefit) at statutory rate |
|
| 35.0 | % |
| 35.0 | % |
State taxes |
|
| 4.5 | % |
| 4.5 | % |
Valuation allowance for Net Loss |
|
| -39.5 | % |
| -39.5 | % |
|
|
|
|
|
|
|
|
Total provision (benefit) for income taxes |
|
| 0.0 | % |
| 0.0 | % |
Deferred income taxes reflect the net tax effect of tax carry-forward items and the temporary differences between the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax assets and liabilities are as follows:
|
| December 31, 2010 |
| December 31, 2009 |
| ||
Deferred tax assets: |
|
|
|
|
|
|
|
Net operating loss carry-forwards |
| $ | 4,910,774 |
| $ | 3,572,439 |
|
|
|
| — |
|
| — |
|
Total deferred tax assets: |
|
| 4,910,774 |
|
| 3,572,439 |
|
Valuation allowance |
|
| (4,910,774 | ) |
| (3,572,439 | ) |
Net deferred tax assets |
| $ | — |
| $ | — |
|
As of December 31, 2010 and 2009 the Company had a valuation allowance on its deferred tax assets of $4,910,774 and $3,572,439, respectively. The increase of $1,338,335 in 2010 and $905,515 in 2009 were attributable to accumulated net operating earnings or losses.
As of December 31, 2010 and 2009, the Company had net operating loss carry-forwards of $11,542,104 and $8,153,915, respectively. Unused net operating loss carry-forwards will expire at various dates beginning 2020.
As of December 31, 2010 and December 31, 2009, the Company had no unrecognized tax benefit and accordingly no related accrued interest or penalties.
The Company has not filed corporate income tax returns since 2005.
NOTE 13. – SUPPLIER CONCENTRATION
Our Cobroxin™ and Zeolite™ products, are sold under an exclusive long-term marketing and distribution agreement from the manufacturer, however we do not possess rights to the formulation. Should the manufacture fail, for any reason to produce the product in the quantities we require, our business may be adversely affected.
F-21
NOTE 14. – CUSTOMER CONCENTRATION
Our Cobroxin™ products comprise essentially all of sales in 2010 and are sold both to retail customers directly and to retailers, grocery and pharmacies. Our products are sold to two significant retailers, who account for 39.5% and 31.5% respectively of our sales during the year ended December 31, 2010. Our sales are made under cancellable agreements. A loss of either of these key customers, for any reason, could adversely affect our business.
NOTE 15. – SUBSEQUENT EVENTS
The Company received a letter from counsel for Nutra Pharma Corp. terminating its distribution agreement for Cobroxin effective April 10, 2011. The Company does not believe that such termination was valid and intends to vigorously pursue its rights in this matter.
F-22